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Abstract 
The aim of this thesis is to investigate the effects of progressive heart failure on the function of the 
Na/K ATPase and intracellular calcium regulation. Progressive heart failure was induced in male 
guinea pigs by constriction of the ascending aorta.  Sham operations were carried out on the control 
group. Hearts were harvested and used for various experiments at 30, 60, and 150 days after the 
aortic constriction operation. Echocardiography was performed on unanaesthetized guinea pigs to 
monitor in vivo changes of contractile function. Significantly smaller fractional shortening was noted 
after aortic constriction although this remained stable during the progression of disease until the 
150 day end point when fractional shortening decreased greatly and circulatory insufficiency 
presented. Heart weight : body weight ratio increased 60 days after the operation, but the lung 
weight : body weight ratio only increased at the 150 day end point. Electrophysiological 
measurements of action potential duration (APD), Ca transients, SR Ca content, and Na/K ATPase 
current were performed to investigate alterations of Ca regulation during the progression of heart 
failure using enzymatically isolated ventricular cardiac myocytes. In end-stage heart failure, APD 
remained prolonged and the function of other mechanisms all declined. These results supported the 
view that compensated hypertrophy developed at 60 days after aortic constriction, and 
decompensation with end stage heart failure occurred about 150 days after the operation.  
At the compensated hypertrophy stage, only Na/K ATPase pump function declined but other 
mechanisms were enhanced or were the same as the situation prior to the constriction. These 
results suggested that alteration of Na/K ATPase function might assist the compensation phase and 
may trigger the decompensatory progression. Since t-tubule remodelling was also observed early in 
the heart failure progression in other study, we used membrane staining with wheat germ agglutinin 
(WGA) to investigate the change of t-tubule density and regularity in guinea pigs with heart failure. 
Our results showed a decrease in density and disorganization with regular but narrower intervals of 
t-tubule arrangement. Immunocytochemical staining of the α1 and α2 isoforms of the Na/K ATPase 
  H Y Ke                                   Calcium Handling During Progression of Heart Failure 
 
2 
 
was further carried out to study their distribution in the sarcolemma when the heart fails. The 
results showed decreased expression of both α1 and α2 isoforms, which is compatible with our 
functional findings of Na/K ATPase pump current decline. Furthermore, corresponding to WGA 
membrane staining, α2 isoforms were found to colocalize with t-tubules. These finding suggested 
that alteration of Na/K ATPase pump function occurs early in the progression of hypertrophy toward 
heart failure, and α2 isoforms may play a more prominent role in regulating Ca handling. 
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1 INTRODUCTION 
    Heart failure (HF) affects around 1-2% of the adult population in developed countries, and is 
prominent in aged people (>70 years old) with a prevalence of ≥10%
1,2
.  In 2011, the prevalence of 
HF in the UK’s over 75 years old population was 20%
3
.  The total healthcare cost for HF in the UK was 
£8,680,892,000 in 2009
4
. Modern medical technologies and improved public health systems have 
prolonged the human lifespan in the past decades. Along with the aging of populations, HF 
treatment and care will be a global health issue in the future. HF represents a syndrome of 
circulatory insufficiency which is caused by a decline in cardiac contractility. At the cellular level, 
calcium (Ca) is the key ion that converts the electrical excitation to produce contraction. Therefore 
the decline in cardiac contractile function is closely related to alterations in Ca handling. 
 
  H Y Ke                                   Calcium Handling During Progression of Heart Failure 
 
2 
 
1.1 Calcium regulation in the heart 
Since the outstanding clinician scientist, Sydney Ringer
5
, discovered that extracellular Ca is 
important for cardiac contraction in 1883, Ca regulation in the heart has been the subject of major 
research efforts designed to increase our understanding of the mechanisms underlying cardiac 
conduction and contraction. In 1952, Sandow
6
 proposed a model that connected and translated an 
electrical stimulation to the contractile response and termed it the excitation-contraction coupling 
(EC coupling) of the muscular response. A hundred years after Ringer’s discovery, in 1983, Fabiato
7
 
proposed that in the normal heart the coupling of electrical excitation to the production of 
contraction involves the interaction of a number of cellular proteins involved in Ca homeostasis. Ca 
influx through the surface membrane (sarcolemma) promotes further release of stored Ca from the 
sarcoplasmic reticulum (SR) via the SR Ca-release channel (the ryanodine receptor, RyR) by a process 
known as Ca-induced Ca release (CICR)
7
. This small, local, transient calcium release from usually a 
cluster of RyRs is called a “calcium spark”
8-12
. Both fluxes of Ca combine to initiate contraction which 
occurs when large numbers of Ca sparks summate spatially and temporally to form a large and rapid 
increase in cytoplasmic Ca concentration. Two main systems are involved in removing Ca from the 
cytoplasm and so inducing relaxation. Ca is pumped back into the SR by the phospholamban (PLB)-
regulated sarcoplasmic/endoplasmic reticulum Ca ATPase (SERCA) and extruded from the cell by the 
sarcolemmal Na/Ca exchange (NCX). The phasic increase and decrease of Ca that gives rise to the 
elements of contraction and relaxation respectively is generally termed the “Ca transient” (see 
Figure 1-1).   
 Introduction 
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 Figure 1-1. Calcium fluxes and Ca regulatory mechanisms in a ventricular myocyte. 
Ca ions enter the cell via the voltage-gated L-type Ca channels (LTCC) in the t-tubule and bind to 
ryanodine receptors (RyRs) in the membrane of the sarcoplasmic reticulum (SR) inducing a 
conformational change in the protein.  This leads to opening of these channels and SR Ca release 
occurs. Ca influx and Ca released from SR bind to troponin-C (TnC), a process that activates the 
myofilaments causing contraction. Ca is then pumped back into the SR by sarco/endoplasmic 
reticulum Ca ATPase (SERCA) and extruded out of the cytoplasm mainly by the Na/Ca exchange 
(NCX), but also partially by the sarcolemmal Ca ATPase and mitochondrial Ca uniporter. The LTCC 
and corresponding cluster of RyRs form the fundamental functional unit of calcium-induced Ca 
release (CICR)- the couplon, which exits within the close approximation of junctional SR (jSR) and 
the t-tubule that is termed a dyad.  
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1.1.1 Action potential in ventricular cardiomyocytes 
    The action potentials of different excitable cells in the heart show different shapes and durations, 
which represent the different ionic currents passing through different ion channels. The action 
potential of ventricular myocytes has a longer duration than that in other cell types for example 
atrial or sino-atrial node cells
11,12
. The action potential provides the stimulus that initiates E-C 
coupling. Its shape is determined by multiple interactions of many ion channels and transporters
11
.  
    The ventricular AP is composed of 5 phases
12
 (indicated in Figure 1-2):  
Phase 0: fast and large depolarization of the cell membrane creates this rapid upstroke. 
Phase 1: early repolarization occurs producing a “spike” on the AP waveform. . 
Phase 2: membrane potential is relatively stable in this plateau stage and repolarization develops  
                slowly. Contraction of myocytes reaches a peak and then starts to relax during this stage. 
Phase 3: repolarization during this stage occurs much more rapidly. 
Phase 4: finally the membrane potential returns to the resting potential and prepares for the next  
                cycle. 
 
1.1.1.1 The phase 0 of the AP 
In the phase 0, the Na channels in the surface sarcolemma sense the depolarization and open to 
produce an inward Na flow, which causes the Na current (INa) and evokes the large upstroke
12
.  
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1.1.1.1.1 The voltage-gated Na channel 
    The functional component of the voltage-gated Na channel is the α subunit, which consists of four 
homologous domains forming the channel pore
12-15
. Each domain is formed by six membrane-
spanning segments (S1-S6). The S4 segment contains a region  that senses the depolarization  and 
moves in response producing conformational changes in the  S5 and  S6 segments that bend to open 
the channel
11,12,15
. This allows the entry of Na ions into the cell.  The Na ions flow down their 
electrical and concentration gradients producing a depolarization that then causes more channels to 
open, producing a large INa that causes a large and rapid upstroke. Although the cell membrane is 
still depolarized, around 2 ms after the Na channels first open they become inactivated and unable 
to pass Na ions by a mechanism of “hinged lid” which is formed by a loop of peptide that connects 
the S3 and S4 segments.  The inactivation of Na channels cannot be removed unless repolarization 
occurs (in phase 3 of the AP).  This produces the absolute refractory period of the AP. No matter how 
large the stimulation is, no action potential can be produced during this inactivated period. After this 
absolute refractory period, some Na channels have returned to their deactivated (closed) status and 
can be opened by a stimulation that is larger than normal. This period is called the relative refractory 
period
11,12
.  
    A P-loop between S5 and S6, which contains the consistent sequence of amino acids (the so-called 
“signature sequence” or “DEKA motif” (D: aspartic acid or Asp; E: glutamic acid or Glu; K: lysine or 
Lys; A: alanine or Ala), forms the selectivity filter of the channel making it reasonably selective for Na 
and some smaller ions (i.e. lithium, Li) over larger ions (e.g. potassium, K).  This occurs by a complex 
electrostatic competition process between the ions and the DEKA motif
12,16
. Mutations of this P-loop 
influence the conductance and the selectivity of the channel, and the channel’s interaction with 
tetrodotoxin (TTX), a neurotoxin that blocks the Na channel specifically
12,17,18
.  
  H Y Ke                                   Calcium Handling During Progression of Heart Failure 
 
6 
 
    The main cardiac form of the Na channel is the NaV1.5, which is coded by the SCN5A gene and is 
less sensitive to TTX inhibition than the other neuronal forms (Kd value > 2μM in the cardiac forms vs 
Kd value around 1-10 nM in the neuronal forms).  
The Vaughan Williams class I anti-arrhythmics bind to S6 of the II and IV domains to block the Na 
channel slowing the upstroke of the phase 0 and decreasing the amplitude of the AP, thus slowing 
the conduction velocity in the heart
19
. Therefore they can be used to treat supraventricular and 
ventricular tachycardias by slowing the speed of conduction of the impulse across the atria and 
through the AV node. Drugs of the class IA subset (i.e. quinidine, procainamide, and disopyramide) 
can also prolong the APD and therefore the refractory period, which lowers the incidence of re-entry 
phenomena and automaticity
11,12,19
. 
 
1.1.1.2 Phase 1 of the AP 
    In phase 1, early repolarization is caused by K channels producing a transient outward current (Ito) 
that is rapidly activating and limits the upstroke. Ito is differently expressed in different cardiac cell 
types, and species, and influences upstroke speed and amplitude, the duration of phase 1 and the 
whole APD
11,12
. Ito has two main components that are Ca-independent (Ito1) and Ca-dependent 
(Ito2)
11,12
. 
    The outward current quickly inactivates and is balanced, and later overcome, by an inward Ca 
current produced by the long-lasting L-type Ca channel (LTCC), the ICa,L. Ca that enters the cell via this 
channel is the trigger for CICR .  
Inhibition of Ito causes the notch to disappear in phase 1, a more positive membrane potential in 
early phase 2, and usually a prolonged APD. This alteration affects ICa,L and the corresponding 
changes in intracellular Ca handling. 
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1.1.1.2.1 The voltage-gated K channels (KV) 
    A typical voltage-gated K channel consists of four α subunits forming the channel pore. Each α 
subunit comprises six membrane-spanning α-helical segments (S1-S6)
20
. It is thought that a similar 
mechanism of voltage sensing occurs as in the Na channel and similar changes in conformation occur 
in the protein to open the pore and allow the K ions to flow though
21,22
.   Inactivation of K channels 
that, for example, carry Ito  is induced by the so called “ball and chain” mechanism, in which a 
shorter “ball” peptide that connects to a longer “chain” peptide  swing into the opened channel to 
block the pore
23
. The positively-charged tetraethylammonium (TEA) ions selectively block these K 
channels
12,24
.  
    A short P loop connecting S5 and S6 forms the selectivity filter of the channel, which contains a 
different the signature sequence of amino acids from the Na channels.  The sequence TVGYG (T: 
threonine or Thr; V: valine or Val; G: glycin or Gly; Y: tyrosine or Tyr) is consistent across many K 
channel isoforms and provides chemically and energetically efficient oxygen binding sites that 
perfectly fit and substitute for the hydration shell of  K ions but are unfavourable for other smaller 
ions such as Na
12,21
. This allows discrimination for K over Na. Ion selection is also determined by the 
size of the pore which excludes those larger ions such as Cs
11,12,22
.      
    The α subunits of the inward-rectifying K channels (e.g. those through which IK1 flows, only consist 
of two membrane-spanning segments (M1 and M2)
12,20
.   
1.1.1.2.2 The L-type Ca channel (LTCC) and ICa,L in the heart  
    ICa,L  ,  was first discovered in Purkinje fibres of the heart by Harald Reuter
25
 in 1967. It activates 
slower than INa at membrane potentials positive to -40 mV and reaches its maximum value about 0 
to +10 mV
11,12
. 
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1.1.1.2.2.1 The structure and function of the LTCC 
    The LTCC is the most common form of Ca channel in the heart and contains α1, α2, β, ϒ and δ 
subunits
11,12,26
. The large α1 subunit is formed by four domains and these form the pore, the 
selectivity filter, the voltage-sensor and the binding sites for agonists and antagonists. The structure 
of the LTCC is similar to that of Na channels. Although the α1 subunit alone can provide a complete 
channel for the current to flow through, its association with the β subunit  can boost the peak 
current, change the voltage dependence of activation and hasten the inactivation kinetics
11,12,26,27
.  
    The inactivation of LTCC is determined by two mechanisms: (1) voltage-dependent inactivation 
(VDI) controlled by membrane potential and (2) Ca-dependent inactivation (CDI) modulated by [Ca]i 
(mainly depends on the Ca released from the SR)
28
. The normal inactivation kinetics of Ca current is 
slower than that of Ito, therefore the declining ICa,L  continues into early phase 2 and balances the 
outward K currents, which contribute to the prolongation of the APD. An alteration in Ca influx via 
the LTCC in turn influences Ito and this changes the shape of the AP
29
.  Harris et al. reported such 
findings in feline cardiac myocytes
30
.  
1.1.1.2.2.2 The regulation of the LTCC 
    The LTCC can be inhibited by the dihydropyridines (i.e. nifedipine and nitrendipine), the 
phenylalkylamines (i.e. verapamil and D600), and the benzothiazepines (i.e. diltiazem).  The LTCC is 
also called dihydropyridine receptor (DHPR) because of its sensitivity to dihydropyridines. The LTCC 
can be modulated (phosphorylated) by Ca/calmodulin-dependent protein kinase II (CaMKII) to 
increase the peak ICa,L amplitude and slow the inactivation, a process is known as facilitation
11,12,26
. 
CaMKII is a serine/threonine-specific protein kinase which is inactive by auto-inhibition unless the 
Ca-CaM complex binds to it unblocking the catalytic site, which binds to ATP and the kinase transfers 
a phosphate group to phosphorylate the LTCC at a threonine site increasing the open probability of 
the channel. There are still other phosphorylation sites in the α1 subunit for other protein kinase 
such as G-protein, protein kinase A and C (PKA and PKC)
26,27
. On one hand, the Gαs subunit of G-
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protein can activate adenylate cyclase to promote the production of cAMP from ATP, which in turn 
activates PKA which leads to phosphorylation of the LTCC. On the other hand, the Gαs subunit itself 
may stimulate the LTCC without the PKA phosphorylation
12,26
. Both ways increase the open 
probability of the LTCC. This mechanism is also widely applied in clinical treatment to increase 
cardiac inotropy. The Gαs-protein pathway also influences the SR Ca release and SERCA function, 
which will be described in the following sections. 
     
1.1.1.3 Phase 2 of the AP 
When the action potential progresses to the plateau phase 2, the cell is still depolarized, and a 
near complete balance of inward and outward currents maintains a relatively stable membrane 
potential.  
    During phase 2, more repolarizing outward currents are activated, mainly IKur, IKr, and IKs, where ur, 
r ,and s refer to ultra-rapid, rapid, and slow
12,31
.  
1.1.1.3.1 IKur 
    IKur flows through the KCNA5 gene coded channel KV1.5 and generally appears in the atria only 
although the mRNA and expressed protein of this channel are both found in the ventricle as well
31
. 
Thus the appearance of IKur may be related to other regulating subunits or proteins. Since it does not 
determine the ventricular APD it can be excluded from the current work. 
1.1.1.3.2 IKr 
    Channels that carry IKr activate at membrane potentials more positive than -40 mV but inactivate 
quickly when those potentials reach +0 mV and more positive. Therefore these channels re-open at 
late phase 2 and early phase 3 when membrane potential returns to be more negative, which 
contributes to the repolarization at early phase 3. IKr flows through the KV11.1 (hERG, human ether-a-
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go-go related gene) channel, which is coded by KCNH2 gene and modulated by a MinK-related 
protein 1 (MiRP1, coded by the KCNE2 gene) and an accessory subunit called minK
12
. The KV11.1 
channel is specifically inhibited by the methanesulphonanilides. Inhibition of the channel by drugs or 
genetic mutations causes the prolongation of the APD
12,32
. This APD prolongation appears on the 
whole heart ECG as a longer QT interval.  Drug or genetically-induced changes to the function of this 
channel produce  long QT syndrome (LQTS) and may be an underlying cause of early 
afterdepolarizations (EADs) and re-entrant arrhythmias
12,32
. 
1.1.1.3.3 IKs 
    IKs is another delayed rectifier current that flows through the channel KV7.1 (also called KVLQT1), 
which is coded by KCNQ1 gene and distributes preferentially in the epi- or endocardium and in the 
base of the heart. This channel may play an important role in transmural distribution of AP. The 
channel is voltage-gated but activates slowly during depolarization until the fast repolarization 
period at late phase 2 and early phase 3. The effect of IKs in repolarization is still controversial. It is 
specifically blocked by chromanol 293B. The KCNQ1-derived channel needs the co-existence of a 
minimal K channel subunit (minK) coded by the gene KCNE1 to form a fully functioning channel. 
Mutation of either KCNQ1 or KCNE1 causes LQTS in the whole heart
12,33,34
. 
 
1.1.1.4 Phase 3 and 4 of the AP     
The repolarization continues and becomes faster in phase 3 until the resting potential is reached in 
phase 4. The current responsible for this final repolarization is IK1 which is large enough to overcome 
any existing inward currents notably. A small outward Na/K ATPase current (IP) also contributes a 
few millivolts to the maintenance of the resting membrane potential
11,12
. 
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1.1.1.4.1 IK1 
    Channels the carry IK1 have the property of inward rectification which can be attributed to a 
voltage-dependent block of the channel by intracellular Mg and polyamines
35-37
. When membrane 
potential becomes more negative during repolarization, the Mg or polyamines unblock from the 
channel and the inward-rectifying K channels (Kir) re-open at membrane potentials negative to -20 
mV.  These channels are not like the α subunit of KV channels that contain six membrane-spanning 
segments, because Kir consists of only two membrane-spanning α-helical segments (M1 and M2)
35-37
. 
Since Kir lacks the voltage-sensor of S4 that presents in a typical KV channel, it is insensitive to 
membrane potential. The extracellular K concentration [K]o plays an important role in modulating 
IK1
12
. A higher [K]o accumulating in t-tubules caused by some pathological conditions such as 
ischaemia increases the outward Ik1, thus influencing the depolarizing upstroke of action potential 
produced by Na influx
12,35
. IK1 channels localize in t-tubules and have a higher density in ventricular 
myocytes. 
 
1.1.1.5 The role of the Na/Ca exchanger in shaping the AP  
The bi-directional ion exchanger, the Na/Ca exchanger (NCX), can bring Ca into the cell creating an 
outward current (reverse mode) in phase 0/1, and can expel Ca out of the cell creating an inward 
current (forward mode) in phase 2 and 3. The direction of ion exchange is governed by intracellular 
Ca and Na concentration combined with membrane potential
11,12
. More details about NCX will be 
introduced in the following sections. 
 
1.1.1.6 Late Na current   
Although almost all Na channels inactivate very quickly after the initiation of action potential 
upstroke, some Na channels remain open or re-open during the action potential creating a very 
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small late Na current, INa,L, that persists through the plateau and may contribute to the prolongation 
of APD
12,38,39
. 
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Figure 1-2. An action potential recorded on an isolated ventricular myocyte from a male guinea pig 30 
days after aortic constriction. 
The duration is around 220 ms. Resting membrane potential is about -85 mV. The maximal upstroke 
potential reached is about 40 mV. The action potential can be classified into phases 0-4 to help identify 
and characterize its various parts and the associated ionic currents. 
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1.1.2 SR Ca release and reuptake 
    When cell depolarization occurs, extracellular Ca enters cell via LTCC and causes an inward current 
ICa,L. The Ca activates clusters of RyRs in the SR membrane that lie directly below the LTCCs. Binding 
of Ca to RyRs opens the channels and causes SR Ca release
7,11,12
. The SR is an independent, 
membrane-bounded intracellular organelle that stores Ca. In proximity to invaginations of 
sarcolemma, the transverse tubule (t-tubule), the tubular SR becomes broad and flat to form  
junctional SR cisternae (jSR)
12
. The space between the t-tubule and the jSR is called the dyad, where 
proteins concerned with Ca regulation and EC coupling colocalize, such as LTCC and NCX in the 
sarcolemma, and RyRs in the membrane of the SR 
12,40-42
. The RyRs are usually grouped in a cluster 
and appose a corresponding LTCC. This local area that contains the LTTC and corresponding cluster 
of RyRs is called a “couplon”, which is a fundamental functional unit for CICR
11,41
.   The amount of Ca 
released from SR is much greater than Ca influx. The local, transient, and small release of Ca from a 
cluster of RyRs is termed a “Ca spark,” and the temporal summation of individual Ca sparks accounts 
for the whole cell Ca transient
8,12
. Because RyRs are relatively insensitive to Ca and the released Ca 
diffuses away quickly from them, Ca sparks can be treated as independent events and usually do not 
trigger neighbouring RyRs to release Ca
12,41
. The synchronisation of activation of many LTCCs with 
their underlying clusters of RyRs plays an important role in efficient SR Ca release and 
contraction
12,30,41,43
 and depends greatly on the integrity and number of t-tubules.   
    Based on the theory of local control of Ca in a microdomain proposed by Stern
44
, more studies 
have focused on the microarchitecture of the dyad and its structural role in the synchronous SR Ca 
release
10,41,43,45-49
. Discovery of the microscopic SR Ca release, “Ca spark”, in the dyad by Cheng and 
colleagues
8
 supported this close structural and functional relationship. Soeller et al.
50
 investigated 
the distribution of EC coupling proteins in the heart by a super-resolution imaging technique and 
brought a better understanding into a nanometer scale. The super-resolution imaging method 
provides a good resolution of 10 nM and also reserves the beneficiary specificity of fluorescence 
imaging
51,52
. Cannell & Kong
10
 examined those results using mathematic methods and also supported 
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this theory. However, more detailed studies about this micro- even nano-architecture of dyad and 
couplon are needed for a better understanding.   
    The open probability of RyRs can be enhanced by being phosphorylated by cAMP- dependent 
protein kinase A (PKA)
53,54
. A FK-506 binding protein (known as FKBP12.6, which is associated with 
cardiac RyR2) plays a modulating role in the opening of RyRs. Stress-induced hyperphosphorylation 
of RyRs causes dissociation of FKBP12.6 from them, which increases the open probability of RyRs 
thus increasing the chances of spontaneous releases that may be pro-arrhythmic
55,56
. Wehrens et 
al.
57
 reported that a deficiency of FKBP12.6 is linked to exercised-induced cardiac death in a mice 
model, which could also explain the mechanism of catecholaminergic polymorphic ventricular 
tachycardia (CPVT), a human autosomal-dominant inherited disorder that is characterized by stress-
induced ventricular tachycardia (VT). 
    Released Ca is extruded by NCX in the sarcolemma and pumped back to SR by SERCA in the SR 
membrane ready for the next CICR cycle. Some Ca ions are extruded by the sarcolemma Ca ATPase 
and taken up into mitochondria by the Ca uniporter, although these two systems only account for 
less than 5% of Ca removal
11,12
. SERCA is one of the P-type ion transporter ATPase family, which uses 
ATP as energy to pump Ca back to the SR
11,12
. It is regulated by an endogenous regulatory protein 
phospholamban (PLB) that usually blocks the SERCA function unless phosphorylated by PKA and 
CaMKII
11,58-60
.   
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1.1.3 Ca removal from the cytoplasm 
    Though there are species differences
11,12,61-73
, SERCA and NCX contribute about 70% and 25% 
respectively towards relaxation
12
.  Bers and Bridge 
74
 investigated this competition firstly in 1989 
using the rapid cooling contractures (RCCs) method to induce SR Ca release and then rewarming to 
induce relaxation  in rabbit ventricular myocytes. They blocked the SERCA and NCX function by 10 
mM caffeine and zero-Na, zero-Ca (0Na, 0Ca) solution respectively. When blocking SERCA reuptake, 
the relaxation was slowed by 70%, whereas it was slowed by 30% when blocking NCX. While 
blocking both mechanisms, the relaxation slowed greatly by more than 1000%. This result suggested 
that SERCA and NCX were the two major mechanisms to produce relaxation.  
    In steady state conditions the amount of Ca efflux is the same as the amount that has influxed via 
LTCCs so that balanced Ca homeostasis is achieved
11,12
. NCX uses the large electrochemical gradient 
between intra- and extracellular Na and Ca concentration to transport 3 Na into the cell and expel 1 
Ca out of the cell (a stoichiometry of 3:1), therefore it is electrogenic
12
. This is the normal forward 
mode of the NCX function. However, in some conditions such as depolarization and when 
intracellular Na concentration ([Na]i) is increased, NCX function can operate in “reverse mode”, in 
which NCX transports 1 Ca into the cell in exchange for 3 Na out of the cell. There are some reports 
that suggest NCX may contribute to CICR
11,12,42
 in this mode. Several studies had reported that NCX 
localizes predominantly in the t-tubule compared with the surface sarcolemma
40,42,45,75-77
, while 
whether it localizes within or nearby the dyad is still controversial
76
. Lederer et al.
78
 first proposed 
the concept of a “fuzzy space” to describe the close spatial colocalization of Na channels, Na/K 
ATPase, and NCX. Furthermore, possible colocalization of  NCX and Na/K ATPase, especially the α2 
isoform of the latter protein, in t-tubule have been reported
79,80
, which indicates a possible close 
regulatory role of the Na/K ATPase in controlling NCX function because Na/K ATPase is the major 
mechanism that regulates intracellular [Na]
42
.   
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    Bassani et al
62
. evaluated the contribution and competition of four mechanisms that responsible 
for Ca extrusion during relaxation: SERCA, NCX, sarcolemmal Ca-ATPase, and mitochondrial Ca 
uniporter, in rabbit ventricular cardiomyocytes
62
. They used rapid and sustained application of 
caffeine to keep RyRs open causing complete Ca release from SR, in other words, omitted the SERCA 
function. They then used 0Na, 0Ca solution to block NCX function, FCCP (Carbonyl cyanide-p-
trifluoromethoxyphenylhydrazone) + oligomycin to block mitochondrial Ca uniporter, and 0Na, 
10mM Ca solution to block the sarcolemmal Ca-ATPase. The results indicated that the SERCA 
removed Ca 3-4 times faster than NCX, while NCX removed around 37 and 50 times faster than 
sarcolemmal Ca-ATPase and mitochondrial Ca uniporter. They also addressed that these four 
mechanisms are nearly totally responsible for relaxation because when blocking all of their functions, 
the relaxation was nearly eliminated.  
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1.2 The role of the Na/K ATPase in a cardiac cycle   
    The Na/K ATPase is a P-type ATPase which was discovered by Skou
81
 in 1957. It is the only Na 
pump that catalyzes ATP and pumps Na ions out of the cell and K ions into the cell to maintain 
adequate electrochemical gradients and resting potential
12,82
. The Na pump regulates intracellular 
[Na] that influences the NCX function and so, in turn, Ca regulation. 
 
1.2.1 Sodium, Na/K ATPase, and calcium handling       
    Na influx triggers the depolarizing event that initiates EC coupling.  The influx of Na would lead to 
a gradual increase in intracellular [Na] which, as detailed earlier, plays an important role in NCX 
function. Further, the large electrochemical Na gradient in cardiomyocytes also provides the driving 
force for other active transporters, Na/H exchanger (NHE) and Na/HCO3 cotransporter (NBC), to 
extrude H or HCO3 out of the cell (both in a 1:1 stoichiometry with Na) to maintain the homeostasis 
of intracellular pH, that is also an regulatory factor for Ca handling
12,42
. Although reverse mode NCX 
can also remove Na from the   cell, the Na/K ATPase is the only mechanism that maintains the 
transmembrane gradients of Na and K. To do this it uses the energy produced from hydrolysis of ATP 
to remove Na against the transmembrane Na gradient and determines the intracellular [Na]. Once 
the Na/K ATPase pumping function is depressed or inhibited, the intracellular [Na] would increase, 
which causes activation of reverse mode NCX and more Ca influx inducing more SR Ca release and 
powerful contractile force. This mechanism explains the inotropic effect of cardiac glycosides and 
steroids that inhibit Na/K ATPase function
11,12,83
.  
    Na homeostasis is governed by the balance of Na influx via ion channels and transporters, and Na 
extrusion via the Na/K ATPase
84
. Na influxes via voltage-gated Na channels, NCX (forward mode), 
NHE, NBC, and Na, K, 2Cl
-
 cotransporter (NKCC). Voltage-gated Na channels and NCX play major roles 
during an APD. For Na extrusion, Na/K ATPase operates in a 3:2 stoichiometry (3 Na ions are moved 
out of the cell and 2 K ions are moved in)
12
, which forms the pump current (Ip).  In addition to the 
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regulation of global intracellular [Na], a potential model of Na microdomains within the cell has been 
proposed to explain alterations in local [Na] without changing the bulk [Na]
42
. Lederer and 
colleagues
78
 proposed the concept of a “fuzzy space” near the dyad describing the co-existence of 
TTX-sensitive Na channels, NCX, and RyRs, where the increased [Na] and depolarization turn the 
nearby NCX to its reverse mode to import Ca and facilitate CICR
78,85
. Studies also revealed that there 
is a Na gradient between subsarcolemmal space and bulk cytosol where the subsarcolemmal Na 
concentration is much higher
86-88
. It seems reasonable that those regulatory proteins colocalize and 
share the signalling of local Na concentration to act efficiently. Sikkel et al.
89
 reported that flecanide, 
an antiarrhythmic agent, reduces Ca sparks and wave frequency by inhibiting INa, rather than 
influencing the function of RyRs in intact rat cardiomyocytes. The reduced INa causes enhanced NCX 
function resulting increased Ca efflux and lower Ca concentration to eliminate RyRs Ca release. 
However, more evidence is needed to support this Na microdomain (even nanodomain) hypothesis 
and to investigate its possible regulatory role in Ca handling
42
. 
 
1.2.2     Subunits of Na/K ATPase 
    The Na/K ATPase consists of three subunits, α, ß, and ϒ. The α-subunit is the largest subunit and 
has the ion-binding and catalytic sites so is responsible for the main pump function. Besides being 
the main part of the pump, the α-subunit is also the binding target for digitalis glycoside inhibitors 
such as digoxin and ouabain, which block the extracellular entry of K
11,12
. The ß-subunit plays a role 
in the proper insertion of the pump in the plasma membrane and changing the protein conformation 
during the transportation of K
11,12
. The combination of α and β subunits can form a functional Na 
pump. The ϒ-subunit  is a member of FXYD family and acts as an accessory regulatory protein which 
is not required for pump function
12
. Phospholemman (PLM) is one of these proteins and highly 
expresses in cardiac myocytes
90
. The amount of phosphorylated PLM determines the activity of the 
pump
82,90-95
, which is regulated by cAMP-dependent protein kinase A and C (PKA and PKC)
82,90
.  
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The α subunit has 4 isoforms: α1-α4. The α1 and α2-isoforms are present in guinea pig, adult mice 
and rat
11,96-98
. In dog and macaque hearts, the α1 and α3 isoforms are detected
99
. The human heart 
shows α1, α2, and α3 isoforms
99
. The α3 isoform is also expressed in hearts of neonatal rats
98
. The 
α4 isoform seems to express exclusively in sperm and be related to sperm motility
12,100
.  
    The α1-isoform plays a role in maintaining the bulk [Na]i. Its affinity for Na relates closely to [Na]i 
with a Km of about 10 mM
12,91
. Its affinity for ouabain (K1/2) ≈ 141 μM
101
. In contrast, the affinity of 
the α2 isoform for Na is lower (Km is about 20-30 mM)
12,91
 but it has a higher affinity for ouabain (K1/2 
≈ 0.38 μM)
101
.  The α2 isoform has been found to be more localized in the t-tubule than the α1 
isoform
102
. Swift and colleagues
103
 have demonstrated that the current due to the α2 isoform of the 
Na/K ATPase and INCX both decreased when the isolated cardiomyocytes were detubulated. This 
suggests that the α2 isoform and the NCX are mainly located in the t-tubular system. Furthermore, 
inhibition of the α2 isoform increased cell contractility as well as INCX, but did not influence the [Na]i, 
which suggests that the α2 isoform may co-localize with NCX in the t-tubule and may influence 
contractility by locally controlling the subsarcolemmal [Na] which influences the function of nearby 
NCX. Lingrel’s group
104,105
 demonstrated that hypocontractility, reduced Ca transients, and 
decreased INCX were found in the α1 heterozygous knockout mice (α1
+/-
, with a decreased α1 isoform 
expression), whereas hypercontractility, increased Ca transients, and enhanced INCX were found in 
the α2 heterozygous knockout mice (α2 
+/-
, with a decreased α2 expression). On the other hand, 
Dostanic et al.
106
 showed in mice that the α1 isoform may regulate Ca handling via an interaction 
with NCX, and found both α1 and α2 isoforms physically colocalized with NCX.  
In the human α1, α2, and α3 isoforms are found in a ratio of 62%: 15%: 23% respectively
107
.  
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1.2.3 Pump dysfunction in heart failure  
    Intracellular [Na] increases in guinea-pig
108-110
, rabbit models
111,112
, and in human heart failure
113
, 
but studies of the mechanisms producing the increase remain equivocal. Some studies have 
observed that influx increases in the failing heart without a change in Na/K ATPase function
111,114
 
whilst others have detected alterations in Na/K ATPase isoform expression
115
 and function
116,117
. The 
pathways for Na entry are completely characterised but involve a slowly inactivating Na current
39
, an 
up-regulated Na/H exchange
118
 or the Na/Ca exchange itself. Another possible mechanism is that as 
Na/K ATPase function is regulated by PLM
119
, the phosphorylation or expression levels of this protein 
change in heart failure
92
 so affecting Na/K ATPase function. PLM may be under-phosphorylated due 
to the down-regulation of β-receptor pathways and the up-regulation of protein phosphatases. 
    In the post-infarction HF rats, disorganization of the t-tubule along with decreased density of the 
α2 isoforms was noted. When the α2 isoform function was inhibited by ouabain in the sham group, 
the contractile function showed a similar picture to that of the HF group. When the authors clamped 
the cells at a high intracellular [Na] (by using wide bore pipette) and then measured Ip and they 
found that the INCX decreased when Ip was activated, however, this decrease in INCX was smaller in the 
HF and α2 isoform-inhibited group. Since the global intracellular [Na] was clamped, the decreased 
INCX indicated that the NCX function was regulated by the change to the local sarcolemma [Na], and 
the α2 isoform was related to the control of the local [Na] close to NCX
120
. Despa et al.
121
 used SWAP 
mice to investigate the effect of ouabain inhibition on Ca regulation. SWAP mice have the relative 
affinities for α1 and α2 isoforms exchanged i.e. swapped. They found that the α2 isoform 
preferentially modulates Ca transients and SR Ca release. Most of the current studies have indicated 
that the α2 isoform of Na/K ATPase regulates Ca handling and contractility via coupling with NCX. 
Rindler et al.
122
 showed that knockout of the Na/K ATPase α2 isoform in mice delayed the 
development of hypertrophy caused by pressure overload. 
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    There is also a very small late Na current, INa,L, that persists through the plateau of APD and 
contributes to prolongation of APD. A larger INa,L can be seen in failing cardiac myocytes, which 
prolongs depolarization thus increasing the APD and hence could be arrhythmogenic
12,38
. Coppini 
and coworkers
123
 investigated electromechanical dysfunction of ventricular myocytes from 
hypertrophic cardiomyopathy (HCM) patients, and proposed that INa,L may play a major role in 
modulating CaMKII pathways causing alterations in Ca handling in those HCM patients. Alterations in 
Ca regulation can be partially reversed by inhibiting the INa,L with its inhibitor, ranolazine, which 
eliminates intracellular Na overload and thus reducing enhanced reverse mode NCX caused Ca 
overload. 
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1.3 The process of cardiac hypertrophy and failure 
Sustained, excessive workload on the heart results in the growth of ventricular myocytes and a 
change in the heart/body weight ratio. Myocardial hypertrophy therefore is a compensatory 
response to provide a sufficient cardiac output to meet the increased circulatory demand. This 
process involves a translation of mechanical stress into changes in cellular signalling pathways that 
cause increased gene expression and protein synthesis. The final reaction leads to remodelling of the 
ventricle that normalizes wall stress and compensates for the increased load.  
In the past decades, many mechanisms involved in producing cardiac hypertrophy have been 
studied. Current investigations point to the CaMKII pathway playing a key role in this process
124-127
. 
In a normal physiological circumstance, the CaMKII (CaMKIIδ isoform appears predominantly in the 
myocardium
128
) is auto-inhibited and inactive, unless it is bound to a Ca/CaM complex when 
intracellular Ca increases.  This process may be important for enhancing EC coupling and heart 
function in response to increased stimulation
124
. However, when long-term or frequent stimulation 
by Ca/ CaM occurs, this enzyme becomes Ca independent or less dependent due to 
autophosphorylation or oxidation of its regulatory domain, and this may produce a more 
pathological response leading to myocardial hypertrophy, failure, and arrhythmias
129-131
. The 
activation of CaMKII in the cardiomyocytes regulates many ion channels, such as voltage-gated Ca, 
Na, and K channels, thus regulating cardiac Ca signalling and causing prolongation of APD
126,132-140
. In 
the SR, on one hand, the CaMKII enhances phosphorylation of PLB resulting in a promotion of SERCA 
Ca reuptake; on the other hand, it phosphorylates RyRs directly causing more SR Ca release. 
Moreover, the CaMKII also regulates the transcription of hypertrophic signalling mediated by the 1, 
4, 5-trisphosphate receptor (IP3R) located near the nuclear envelope
141-143
. Some neurohumoral 
agonist signalling (i.e. the β-adrenergic stimulation) also activates CaMKII through G-protein coupled 
receptors (GPCRs), the activation of CaMKII translates the stimulation into hypertrophic gene 
programing to induce hypertrophy
127,144
. Physiologically, these CaMKII mediated actions increase 
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cardiac contractility; however, a chronic, long-term activation of CaMKII produces adverse 
consequence such as pathological hypertrophy leading to heart failure and arrhythmias
124,126
. 
   In time, the properties of the hypertrophied myocardium become abnormal and its contractile 
function becomes impaired. With progression of disease and increasing wall stress, the transmural 
forces acting on the left ventricle tend to dilate the heart, further increasing wall stress. The 
compensatory mechanisms become less effective and eventually left ventricular failure ensues. The 
development of myocardial hypertrophy and failure therefore falls into three stages:  developing 
hypertrophy followed by compensatory hypertrophy then decompensated hypertrophy (or heart 
failure) (Figure 1-3).  
    Mann
145
 proposed a hypothesis to describe heart failure in the following three aspects: 
cardiorenal, haemodynamic, and neurohumoral, and current therapeutic strategies are aimed at 
alleviating the symptoms arising from the aberrant function of the above “aspects”.  Although the 
cellular processes underlying the decline in contractile function are gradually becoming better 
understood, little is known about how they change during progression from hypertrophy to heart 
failure. Evidence suggests that cellular mechanisms responsible for regulating intracellular calcium 
levels play a large role
146-150
. 
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Figure 1-3. Progression of hypertrophy toward heart failure.  
When persistent work-overload occurs in the heart, the mechanical stress is translated into 
neurohumoral signalling which induces growth and a thickening of myocardium to compensate the 
transmural stress. Long-term stimulation cause decompensation and heart failure develops, when 
the heart is altered in haemodynamics and morphology. (from Ziad Taimeh, et al.Nature Reviews 
Cardiology 2013;10: 519-530) 
 
  H Y Ke                                   Calcium Handling During Progression of Heart Failure 
 
26 
 
1.4 Alterations in Ca regulation in hypertrophy and heart failure 
Hypertrophied and failing cardiac tissue displays poor contraction and relaxation
151-154
. The 
findings in whole tissue can also be observed in single cells suggesting that the poorer function 
exhibited by hearts nearing failure is a consequence of systems failing at the cellular level. Myocytes 
isolated from the hearts of patients with dilated or ischemic cardiomyopathies when compared with 
those isolated from healthy donor hearts had Ca transients which were slower to relax, diastolic Ca 
levels which were higher, and peak Ca levels which were smaller
155
. Animal models of heart 
failure
156,157
 and cardiac hypertrophy
158,159
 show similar features. The cellular locus for the poorer 
function appears to be the SR
55,56,72,160,161
.    
 
1.4.1 Changes to action potential duration in hypertrophy and heart failure 
Prolongation of APD has been reported widely in both human and animal models of hypertrophy 
and heart failure
29,155,162-166
. Among these studies, a transient outward current (Ito), that contributes 
to produce the early repolarization in the APD phase 1, was found to play an important role in the 
prolongation of APD
29,164,167-171
. Terracciano et al.
172
 reported that prolongation of APD increased SR 
Ca content in guinea pig ventricular myocytes. Naqvi et al.
173
 demonstrated that the prolongation of 
APD in hypertrophied rabbit cardiomyocytes was related to alterations in Ca regulation. Increased SR 
Ca content and Ca transients with a more efficient EC coupling were also shown in rat ventricular 
cardiomyocytes stimulated with long APD simulating the post-myocardial infarction APD
167
. 
Therefore investigating changes of APD during progression of heart failure might help us to 
understand alterations in Ca handling.  
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1.4.2 Ineffective Ca release from the SR and Ca leak 
Phosphorylation of some SR Ca handling proteins, particularly the ryanodine receptor (RyR), may 
have important ramifications in heart failure. In a series of experiments
53,174
 the Marks group 
showed that RyRs are hyperphosphorylated in heart failure resulting in dissociation of a regulatory 
protein FKBP12.6 from the receptor complex. This regulatory protein is thought to play a role in 
regulating the gating of the release channel and its dissociation results in an increase in open 
probability because the RyRs become more sensitive to Ca. In a normal physiological environment, 
such phosphorylation of the RyRs complex would increase the gain of EC coupling resulting in 
increased contraction. Marks and colleagues viewed the response in heart failure as maladaptive 
because the pathophysiological consequence is a leaky SR in diastole that exacerbates the depletion 
of the SR Ca stores with the coexistence of ineffective SERCA function. This mechanism of leaky RyRs 
caused by dissociation of FKBP12.6 also explains the therapeutic benefit of β-adrenergic blockers in 
HF patients
55
. When a stress induces β-adrenergic stimulation, the G stimulatory (Gs) protein is 
activated to promote cyclic adenosine monophosphate (cAMP) being produced from ATP
12
, which 
then activates PKA inducing hyperphosphorylation of RyRs which causes FKBP12.6 depletion
55,56
. By 
blocking β-adrenergic receptors, this Gs protein stimulating pathway can be inhibited which prevents 
contractile dysfunction and arrhythmogenesis caused by SR Ca leak
56,175,176
. This RyR “leak 
mechanism” also links to catecholaminergic polymorphic ventricular tachycardia (CPVT), a rare 
inherited disease caused by mutations in RyRs genes which can cause stress-induced sudden cardiac 
death
57,177
. Defective operation of the SR Ca release channels has also been demonstrated in single 
cells isolated from rabbits with chronic left ventricular dysfunction
178,179
. Based on this hypothesis, a 
Ca release channel stabilizer, Rycals, a derivative of the 1,4-benzothiazepine JTV-519, has been 
developed and proved to be effective in reducing arrhythmia (ventricular tachycardia and fibrillation, 
VT/VF), preventing HF progression after MI, and improving skeletal muscle contractile force in 
animal models
56,180-182
. The drug, Dantrolene, which has been used to prevent malignant 
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hyperthermia occurring during anaesthesia in patients with RyRs mutations, is reported to be 
potentially beneficial in preventing CPVT
183
.     
Nevertheless, the failure of the SR to release Ca effectively in these disease states could also be 
due to changes in the density of RyRs or the ratio of the cluster of RyRs to LTCC. There were fewer 
RyRs in the hearts of aortic-banded rats exhibiting severe hypertrophy compared with sham 
controls
184
 and, in three studies using different models (myopathic hamster hearts, pacing-induced 
failure in dogs and hypertrophy produced by aortic constriction in the rabbit), there was no 
difference in LTCC density but significant decreases in RyRs density
185-187
. There is also evidence in 
heart failure of reduced mRNA coding for the RyRs
188,189
.   Therefore a reduced ability of the SR to 
release Ca may also arise from an alteration in LTCC/ cluster of RyRs stoichiometry and this may 
affect the efficacy with which the LTCC can recruit clusters of SR Ca release channels.  
In addition to the LTCC/RyRs stoichiometry, the concept of Ca signalling microdomain, initially 
proposed by Stern et al.
44,190
 has been expanded and anticipated to change in hypertrophy and heart 
failure. Gomez et al.
191
 first reported that the SR Ca release was reduced but the densities of the 
trigger Ica and RyRs were normal. They proposed that the defective EC coupling was caused by a 
structural alteration in the dyad.  Along with the advancement of imaging techniques, we have 
better understanding about this ultrastructure and its alterations in disease
41,43
. More details about 
the functional-structural changes involving t-tubule and Ca handling proteins in hypertrophy and 
heart failure will be described in a later section.    
 
1.4.3 Reduced Ca uptake into the SR 
Hypertrophied or failing hearts show reduced levels of SERCA protein and its mRNA
192-194
. De la 
Bastie and colleagues
192
 first demonstrated that the SERCA2 expression was down-regulated in a 
pressure-overloaded rat heart failure model. Feldman et al.
195
 supported this finding and reported 
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that down-regulation of SERCA2a was found in the transition from compensated to decompensated 
hypertrophy in an aortic-banded rat model. The amount of PLB which regulates SERCA is also found 
reduced probably to compensate the decreased SERCA function
196
. These findings would account for 
the decrease in Ca uptake into SR vesicles in the cells isolated from hypertrophied or failing 
hearts
188,197-199
. In human heart failure and in animal models of the disease, where SERCA protein 
levels and activity are decreased and severe contractile dysfunction is present, over-expression of 
the protein restores systolic and diastolic function. Modifying cellular Ca regulation by 
overexpressing SERCA also reduces ventricular arrhythmias
200
 and improves haemodynamic, 
echocardiographic and molecular biology assessments of cardiac function
201
.  
Jessup and colleagues firstly applied this concept in a clinical trial using adeno-associated virus 1 
(AAV1) for delivery of SERCA2a complementary DNA in patients with advanced heart failure, the 
Calcium Up-regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) 
gene therapy trial 
202,203
. This trial has shown the efficacy and safety of gene therapy for heart failure 
treatment in human, however, whether the gene therapy could overrule other alterations in Ca 
handling mechanisms during progression of heart failure and the issue about the low transducing 
efficacy  and the neutralizing antibodies of adeno-associated virus  are still challenged
204,205
. A 
further phase IIb trial, CUPID 2, is being performed with the same high dose on more patients with 
NYHA Fc II-IV (NYHA Fc III-IV in the previous phase II trial) to evaluate efficacy and safety. The 
currently available data shows encouraging results
206
.  
 
1.4.4 Alterations in Ca extrusion 
Reduced SR Ca content can be caused not only by decreased SERCA expression and activity, but 
also by increased expression of the Na/Ca exchange (NCX) because the two transporters compete 
for intracellular Ca while bringing about relaxation.  
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In heart failure there is evidence of increased expression of the NCX
200,201,207
. Studer and 
colleagues
208
 reported that the gene expression of NCX increased in human heart failure. This 
alteration in NCX is also noted in most rabbit, dog, and guinea-pig HF models
209-212
. By itself, this will 
alter the competition between uptake and efflux mechanisms favouring more Ca efflux from the cell 
and less loading of the SR. However, the action of NCX also depends on intracellular Na 
concentration ([Na]i) , Ca concentration ([Ca]i) and membrane potential. All of these parameters 
change when heart failure occurs. The major mechanism that controls [Na]i is Na/K ATPase, which 
will be introduced in the following section. 
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1.5 Transverse tubules 
    The transverse tubules (t-tubules) are the invaginations of the external membrane ( surface 
sarcolemma), and account for 21-33%
11
 of total sarcolemma surface area. In cardiac and skeletal 
muscle cells the t-tubules facilitate efficient EC coupling (see Figure 1-4). These structures penetrate 
from the surface into the centre of the cell in the transverse in direction but also stretch 
longitudinally and obliquely, Scriven et al.
45
 named this system as “transverse-axial tubule system” 
(TATS). However, we here still use the usual term t-tubule to refer to this network. 
 
1.5.1 Colocalization of Ca regulatory proteins in the t-tubule and Ca microdomain 
    Evidence has shown that ion channels and transporters that regulate CICR colocalize in the t-
tubules more than in the surface sarcolemma
41,43,49
. Despa et al.
40
 used the method of detubulation 
of t-tubules on rat cardiomyocytes and reported that the functional density of NCX and Na/K ATPase 
is higher in the t-tubules than surface sarcolemma. Greene et al.
213
 reported that SERCA2b 
expression in mice cardiomyocytes is preferentially localized in the jSR that is close to t-tubule. Both 
of these indicate the t-tubule structure also plays an important role in Ca removal. It not only makes 
contraction proceed efficiently and synchronously, but also relaxes the cell adequately by an 
efficient removal of Ca through the colocalized NCX.   
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Figure 1-4. T-tubule structure and colocalization of Ca handling proteins.  
This figure indicates that the t-tubule is the invagination of surface sarcolemma. Proteins associated with Ca 
handling mechanisms, such as voltage-gated L-type Ca channel (LTCC), Na/Ca exchange (NCX), and Na/K 
ATPase, colocalize in the t-tubule. The ryanodine receptor (RyR) that control CICR is closely adjacent to the 
LTCC. The LTCC and corresponding cluster of RyRs form the fundamental functional unit- couplon. This 
micro-environment makes E-C coupling and CICR induced contraction and the following relaxation more 
efficient.  
 
 Introduction 
 
33 
 
1.5.2 Alteration of t-tubule in heart failure 
    Dysregulation of t-tubules has been found in both human and animal models of heart failure
49,214-
221
. Structural deformity and decreased density of t-tubules are noted in heart failure. Louch and 
colleagues
222
 showed that decreased t-tubule density causes dyssynchrony of SR Ca release leading 
to slower and smaller Ca transients in cultured pig and failing human cardiomyocytes. Sipido’s 
group
223
 used a myocardial infarction (MI) model in pig to investigate the relationship between t-
tubule remodelling and SR Ca release. Their experiments demonstrated reduced t-tubule density 
and Ca transient amplitude post MI. Despite SR Ca content increased, delayed Ca release was found 
in the area with lower t-tubule density. However, the ICa,L did not change but, which means t-tubule 
remodelling in MI altered the mechanism of Ca release and influenced the synchrony of SR Ca 
release
223
. Wei et al.
221
 found that the t-tubule changes occurred early during the progression from 
hypertrophy toward heart failure in a rat HF model. Although remodelling and loss of regularity of t-
tubules is known to be related to contractile dysfunction of cardiomyocytes, the underlying 
mechanisms of possible compensated response to heart failure and the changes to Ca regulatory 
proteins in t-tubules need to be further studied. 
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1.6 Aims of the thesis 
Heart failure is one of the leading causes of morbidity and mortality in modern societies and has 
become a global health issue. When heart disease progresses to end stage heart failure, heart 
transplantation is the only destination treatment for this condition. After the first successful human 
heart transplantation performed in 1967 in South Africa by Dr Christian Barnard, efforts have been 
made to improve the surgical outcome and prolong the survival duration by improvement in  
surgical techniques, conservation solution for organ transportation, and, most importantly, 
immunosuppression for the prevention of rejection. These improvements have prolonged the 
median survival time post heart transplantation. According to the latest adult heart transplantation 
report by the International Society for Heart and Lung Transplantation (ISHLT) in 2013, the median 
survival has increased from 8.4 years in 1991 to 10.7 years in 2001
224
 (see Figure 1-5).  
However, the major challenge in heart transplantation is the severe shortage of donor hearts.  
During 2007-2010 in the US, 10,159 adult (≥18 years old) patients were on the waiting list for heart 
transplantation
225
. Among these patients, 1,054 (10.4%) were unable to receive donor hearts and 
died. Only 5,720 patients were offered matched hearts and had the opportunity for transplantation. 
Figure 1-6 shows data collected from a worldwide study that indicates less than 4000 heart 
transplantations were actually performed annually in recent years. This indicates an imbalance in 
donor heart supply and demand. Devices, such as LVAD (Left Ventricular Assist Device), RVAD (Right 
Ventricular Assist Device), and TAH (Total Artificial Heart) were developed to support patients in 
end-stage heart failure (Figure 1-7)
224
 but most of these can only be used as a bridge to heart 
transplantation and are not destination therapies because the issues of long-term anticoagulant 
usage caused bleeding and stroke. Device malfunction and device-related infection are still 
challenging
226
. On one hand, we need to enlarge the donor pool. On the other hand, we should keep 
patients alive on the waiting list, or even decrease the demand for transplantation by blocking the 
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progression toward heart failure. This depends on knowing the underlying mechanisms of calcium 
handling defect and the decline in contraction that occurs during the progression. 
    Although the underlying cellular mechanisms of heart failure are gradually being better 
understood, the changes to these mechanisms during the progression of hypertrophy toward heart 
failure have not been well studied. This study is aimed at characterising the function of the whole 
heart in vivo, to determine the function of Ca regulatory proteins and cellular contraction 
mechanisms in vitro, and to investigate corresponding changes in Na/K ATPase function and 
isoforms ratios at various time points during the progression from hypertrophy to heart failure.  
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Figure 1-5. Survival statistic data after heart transplantation in adults by International Society of    Heart and 
Lung Transplantation (ISHLT). 
The latest (1992-2001) median survival year has reached 10.7 years. (From Lars H. Lund et al., J Heart Lung 
Transplant. 2013; 32: 951-964) 
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Figure 1-6. Annual numbers of heart transplantation performed in all ages worldwide. 
In recent years, the annual numbers of heart transplantation are around 4000, which means many 
patients remain on the waiting list. (From Lars H. Lund et al., J Heart Lung Transplant. 2013; 32: 951-
964) 
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Figure 1-7. Percentage of recipients that were bridged by LVAD, RVAD, and TAH or a 
combination of devices. 
Along with the development of ventricular assist devices, more and more patients receive such 
therapy as a bridge to heart transplantation. (From Lars H. Lund et al., J Heart Lung Transplant. 
2013; 32: 951-964) 
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2 METHODS 
    The main methods used in the work are detailed here. Any variation and modification in 
techniques for a specific experiment will be stated in the relevant chapter.   
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2.1 Animal Models 
Male Dunkin-Hartley (D-H) guinea pigs (GP) were used for animal studies because they have 
similar ECG, ionic currents related to APD and EC coupling with humans
11,227,228
. They were housed 
singly at 21±1
0
C on a 12h light : dark cycle and provided with standard diet and water ad libitum. All 
studies were carried out with the approval of the Home Office, United Kingdom, under project 
license 70/7401 held by Dr MacLeod. Animal surgical procedures and perioperative management 
were carried out in accordance with the United Kingdom Home Office Guide on the Operation of the 
Animals (Scientific Procedures) Act 1986, which conforms to the Guide for the Care and Use of 
Laboratory Animals published by the U.S. National Institutes of Health under assurance number 
A5634-01. 
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2.2  Guinea pig aortic constriction 
    All surgical procedures were performed on adult male D-H guinea pigs weighing 350-450g. Animals 
were assigned to aortic constriction (AC) or control (sham) groups randomly.  
 
2.2.1 Medication and anaesthesia 
    Animals were given premedication of atropine sulphate 0.05 mg/kg (Atrocare 600µg/ml, 
Animalcare Limited) to reduce the oral and nasal secretions and facilitate endotracheal intubation. 
Before endotracheal intubation, animals were placed in an induction chamber and a 4% Isoflurane 
(Isoflurane-Vet, Merial)/ oxygen mix was delivered into the chamber. Once animals were 
anaesthetized, lidocaine (Xylocaine 10mg, AstraZeneca) spray was applied prior to endotracheal 
intubation with a non-cuffed endotracheal tube (Portex, ID 2.0, OD 3.0). After intubation, 
anaesthesia was maintained with 1.5~2% isoflurane inhalation in oxygen. Animals were ventilated 
with a Zoovent Mini ventilator (Triumph Technical Services) at 70 ml/kg, 70 cycles/min. End tidal CO2, 
peripheral oxygen saturation, and pulse rate were monitored with a Capnovet-10 (Vetronic Services) 
and pulse-oxymeter (SurgiVet, Smiths Medical). Prophylatic antibiotics (Enrofloxacin (5%, Baytril)) 
and analgesic (Carprofen (Rimadyl, Pfizer)) were given after a stable anaesthesia had been achieved. 
Local anaesthesic was administered (Bupivacain (Vetergesic, Alstoe Animal Health)) by subcutaneous 
injection around the incision site. 
 
2.2.2 Surgical procedures 
    Animals were put on a heat-pad in a right-lateral supine position and the left forearm was 
retracted towards the head to allow full access to the left chest wall. Fur was shaved and skin 
sterilized with povidone-iodine (Videne Alcoholic Tincture, Adams). Sterilized dressings were used to 
cover the rest of the animal so that there was only exposure of the operative area. Sterilized surgical 
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instruments were used. Thoracotomy was then performed via an incision in the left chest wall above 
the second intercostal space. After the pericardium was opened, the aorta was constricted by a PTFE 
ring with a 2 mm diameter hole that produced constriction, but not occlusion of flow. The ring was 
positioned just below the first branch of the aortic arch. After a 20G intravenous infusion catheter 
was placed as a chest drainage tube, the intercostal incision was closed by 4-0 Prolene (Johnson and 
Johnson Medical Ltd, UK) and the muscle and skin were sutured layer by layer with 4-0 Vicryl and 3-0 
Nylon respectively. Isoflurane was discontinued when suturing was completed and 100% oxygen was 
supplied. Residual intra-thoracic air was aspirated via the chest tube to recover the negative intra-
thoracic pressure. Monitoring of end tidal CO2, peripheral oxygen saturation, and pulse rate were 
continued. After recovery of muscle tone and spontaneous breathing, the endotracheal tube was 
removed. Oxygen was delivered via a face mask according to the reading of the peripheral oxygen 
saturation value. The operated animal was kept and observed in an oxygen-enriched, temperature-
controlled recovery chamber for an hour and then returned to an individual cage for post-operative 
observation and care. The total operation time from initial premedication to placement in the cage 
was around 50 ± 5 minutes. Sham operations were also done with the same procedure without 
banding the aorta. 
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Figure 2-1. Medication, instruments, and pre-operative preparation for animal surgery of aortic 
constriction on guinea pigs.  
(A) Medications used for operation and anaesthesia. (B) Instruments for endo-tracheal (E-T) intubation. (C) 
Ventilator, pulse-oximeter, and end-tidal CO2 detector. (D)Right lateral supine position and illustration of 
constriction of the ascending aorta. 
  H Y Ke                                   Calcium Handling During Progression of Heart Failure 
 
44 
 
2.2.3 Post-operative care 
    Sawdust was not used as a bedding material inside the cage. Instead paper tray liners prevented 
contamination of surgical wound. Water and standard dry food were supplied as usual. A wooden 
tongue depressor was introduced for the animals to chew. This prevented them from chewing their 
wound sutures- a common occurrence. One day after the operation, carprofen (Rimadyl 20mg in 
400ml water) was given orally for 4 days to maintain post-operative analgesia. The surgical wound 
was checked everyday for the first 3 days after the operation, and iodine powder re-applied on each 
day. The primary healing of the wound was usually complete within 5-7 days after the operation. If 
needed, re-suturing was performed under the project license 70/7401 if sutures became dislodged 
causing an open wound. Additional antibiotic treatment was given if necessary on the advice of the 
vet if wound infection had occurred. Then GPs were sacrificed for experiment approximately 30, 60, 
or 150 days after the operation or when the humane endpoints were reached. The human endpoints 
were when animals had severe cardiopulmonary distress symptoms such as dyspnea and cyanosis, 
and uncontrolled wound infection causing severe pain and distress.   
 
2.2.4 The challenge of animal surgery and technical refinements 
In the beginning, we used an inhalation mask for the induction of anaesthesia, but the animals 
varied in the depth of anaesthesia produced by the mask route, and this subsequently caused 
difficulty with endotracheal intubation. We then tried to use muscular injections of ketamine 
hydrochloride (Ketasat, 100mg/ml, Fort Dodge) and xylazine (Rompun 2%, Bayer). However, these 
animals (4/103) either died during anaesthesia or never recovered. Finally, we tried isoflurane 
inhalation in an induction chamber combined with diazepam injection intra-muscularly, which led to 
the successful induction of anaesthesia. 
With a successful induction of anaesthesia, the next challenge was to maintain anaesthesia depth 
and positive mechanical ventilation of the correct amount during the operations. In most 
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circumstances, we decreased the isoflurane concentration from 4% to 1.5-2% once induction had 
been achieved and this produced an adequate depth of anaesthesia.  In some rare cases (2/103), the 
GPs died under anaesthesia prior to the surgical procedures. The cause of death was suspected to be 
an adverse reaction to Isoflurane causing arrhythmia because there was sudden cardiac arrest 
without prior cardiopulmonary distress signs.  
Initially, we used a volume control mode ventilator (Harvard rodent ventilator model 683, Harvard 
Apparatus) for mechanical ventilation during the operation. However, 4 animals died after a sudden 
drop of O2 saturation. These 4 animals came from the same batch of GPs, therefore some congenital 
pulmonary defect was considered to cause the event. Post-mortem autopsy was performed on one 
involved GP. The lungs grossly showed suspicious bleb formation. The biopsies of lung were sent to 
the vet for pathological examination, however, the result showed no abnormality. Another 
consideration was that the ventilator caused hyperventilation which produced pneumothorax. To 
exclude this, we changed to a pressure-control mode ventilator (Zoovent Mini, Triumph Technical 
Services, UK) which has an airway pressure monitor. The normal airway pressure for GPs we 
observed was around 15-25 cmHg. With this pressure control ventilator the mechanical ventilation 
for all subsequent animal operations was carried out smoothly without further pulmonary 
complications.  
Since our animal model was aimed at inducing heart failure, the aortic constriction is severe. Some 
animals could not cope with the increased aortic pressure and suffered acute heart failure and death 
within 24 hrs. Initially we used GPs that weighed around 500-600 g and in 4 of these animals the 
heart rate decreased greatly followed by a drop in O2 saturation, after placement of the aortic clip. 
The lungs of these animals showed congestion and pulmonary edema likely caused by a sudden 
increase of aortic pressure causing backward blood flow and severe volume retention. Therefore we 
used GPs with lower body weight around 350-450 g. These animals had smaller aorta diameters and 
could tolerate the increase of aortic pressure. In these ways we improved the intra-operative 
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mortality rate. Despite these careful refinements some animals (7/103) still developed acute heart 
failure within 24 hours after the operation. Detailed complication and mortality data are described 
below. 
 
2.2.5 Complications 
    Over the course of these studies a total of 103 operations were performed. Of these, 87 recovered 
from surgery and 72 survived until experimental end points. The surgical mortality rate was 15.5%. 
Complications causing death are detailed in  
Table 2-1. Non-fatal complications included (1) wound dehiscence due to removal of one or more 
sutures by the animal gnawing in 2 cases (1.9%) and was re-sutured successfully, (2) wound infection 
occurred in 6 cases (5.8%) and most of them were managed conservatively with topical antiseptic 
but 1 needed further antibiotic treatment. In all such cases the wound closed fully by secondary 
intention within a week. 
 
Complication Number of Animals % of Cases 
Anaesthetic cause or ventilation issues  9 8.7% 
Intra-operative bleeding 3 2.9% 
Intra-operative acute heart failure with pulmonary 
edema 
4 3.9% 
Sudden death within 24h after procedure but after 
recovery 
7 6.8% 
Sudden death after 24h  5 4.9% 
Culled due to humane end point being reached 3 2.9% 
 
Table 2-1. Fatal complications of GP surgery. 
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2.3 Echocardiographic examination of progression of hypertrophy 
toward heart failure 
M-mode echocardiographic measurements were carried out with a S-12 paediatric echo probe 
(depth: 3 cm, frequency: 88 Hz) on a Agilent HP 5500 cardiac echo machine at discrete time points 
(pre-operation, 30 days after operation, and then every 30 days until 150 days after operation) to 
assess the degree of ventricular function and left ventricular hypertrophy in vivo. This examination 
on the unanaesthetized animal needed two people to perform. One held the tested GP in a semi-
supine position to expose the chest region. The other one operated the echo probe and adjusted the 
position to reach a good angle to obtain a clear image for measurement. The tested guinea-pigs 
were fully alert without any sedative or anaesthetic medication to prevent drug influence on heart 
function. These images were all tape recorded for further analysis. 
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Figure 2-2. M-mode echocardiographic examination of fraction shortening (FS).
Distance between + indicates left ventricular internal dimension in systole (LVIDs) as 0.329 cm
Distance between x indicates left ventricular internal dimension in diastole (LVIDd) as 0.625 cm
According to these data, the fraction shortening 
 
could be calculated as 47.5%. 
 
 in this case. 
 in this case. 
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2.4 Isolation of cardiomyocytes for experiments 
The electrophysiological and contractile experiments were carried out on enzymatically-
dissociated cardiac myocytes from sham-operated and aortic banded guinea-pigs using collagenase 
(Liberase TL 5mg, Roche) and a Langendorff perfusion system with constant pressure and flow.  
 
2.4.1 Cell isolation procedures 
Animals were killed by cervical dislocation after being anaesthetized by Isoflurane inhalation. 
Heart and aorta were explanted quickly and placed in cold oxygenated normal Tyrode (NT) solution 
containing heparin (10KU/Litre) to prevent clotting. The heart was trimmed free from adherent 
tissue and then the aorta was cannulated and the heart retrogradely perfused at 37
0
C with the pre-
oxygenated, heparinized normal Tyrode (NT) solution for 3-4 minutes to clear out the blood using a 
Langendorff perfusion system. The heart was surrounded by a heated jacket, to maintain the air 
temperature at 37
0
C. The heart usually started to beat at its intrinsic frequency following a few 
minutes of perfusion with NT solution. Perfusion was then switched to “low calcium solution” (LC) 
for 4 minutes at a steady flow of 6-8mL/min/g, followed by perfusion with re-circulating enzyme 
solution (ES), containing 5mg of collagenase (Liberase TL 5mg, Roche), for 16-18 minutes depending 
on the extent of digestion. The heart normally stopped beating after perfusion with LC solution in 10 
seconds. During perfusion with ES, the heart became swollen and flaccid. The texture of the 
ventricular muscle was tested using forceps. When the muscle was soft and the size of the heart 
became around 1.5-2 times larger, the left and right ventricles were cut down from the cannula into 
a small volume of the collagenase-containing ES. The ventricular muscle was chopped onto 2-4mm
3
 
sections and transferred to a tube containing 10mL of the same enzyme solution and gently shaken 
for 5 minutes at 37
0
C with 100% O2. The tissue was filtered through a piece of 300µm nylon gauze. 
The cell suspension was centrifuged at low speed of 300rpm for 1 minute, and the supernatant 
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discarded. The resulting cell pellet was re-suspended in pre-oxygenated (100% O2) KB solution and 
shaken gently. This cell suspension was ready for experimental use.  
These methods are similar to those described elsewhere
173,187,229
.   Using single cardiac cells allows 
more experiments per heart and therefore reduces the number of animals used. 
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(A) (B) 
(C) 
Figure 2-3. Set-up used for enzymatic isolation of GP cardiomyocytes. 
(A) Langendorff perfusion set-up. (B) Enzyme used: Liberase TL 5mg, Roche. (C) The GP 
heart was attached to the cannula of Langendorff system for perfusion. 
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2.4.2 Tricks in isolating cardiomyocytes 
Although the methods of enzymatic isolation of cardiomyocytes were well established, we 
encountered some difficulties when isolating GP from hearts that had been removed from animals 
with aortic constriction. The yield of viable ventricular myocytes was much less from this group of 
animals.  
Isolating cells from the control group was successful after modification of protocols used for rat 
hearts cells, however, isolation of cardiomyocytes from the AC group in HF was still challenging. In 
this group (150 days after AC), the hypertrophy of hearts was prominent and the ventricular tissue 
was tougher and less digestible perhaps indicating more fibrosis. Such fibrosis might cause poor 
coronary perfusion and thus make isolation of single cells more difficult. To improve the perfusion, 
we increased the perfusion pressure to offset the higher coronary resistance. We also increased the 
perfusion time according to the digestion status of muscle. However, the cell yield was still less than 
50%, which might also indicate that many of the ventricular cardiomyocytes failed to tolerate the 
reintroduction of Ca or the isolation process itself. 
Besides the factors of the heart condition and species difference, the activity of enzyme was also 
an important issue that influenced the result of cell isolation. Liberase TL is an enzyme with 
combination of collagenase I and II, which has been used for isolating GP cardiomyocytes in our 
group successfully. However, we found the enzyme activity was not constant in every batch of the 
enzyme. When changing to a new batch of enzyme, the perfusion time needed to be adjusted 
accordingly. Therefore, we would use a GP from the control group to test the enzyme activity and 
set a new baseline. 
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2.5 Electrophysiological measurements of Ca regulation    
    Electrophysiological measurements were performed on enzymatically-isolated ventricular 
cardiomyocytes using switch-clamping with high resistance microelectrodes
230-232
 to minimise cell 
dialysis. Preserving the intracellular milieu may have important consequences in investigations of 
intracellular Ca regulation. Sharp microelectrodes with resistance around 20-30 MΩ were made from 
glass tubing (Havard Apparatus GC150F-15) by a microelectrode puller (Sutter Instrument CO.). The 
pipettes were filled with solution containing 2M KCl, 10mM HEPES, 100μM EGTA, pH adjusted to 
7.20 with KOH. Experiments were carried out at 37°C. The required signals were recorded with an 
Axoclamp-2A amplifier in conjunction with Clampex 10.2.0.12 acquisition and analysis software 
(MDS Analytical Technologies). Action potential duration, indices for changes in Ca regulation, such 
as SR Ca content, Ca transients, and Na/K ATPase current were measured using well described 
techniques currently in use in the laboratory
187,229,233-235
.  
 
2.5.1 Measurements of action potential duration 
    Action potential duration (APD) was measured with current-clamp. The isolated myocytes from 
both control and experimental groups were continuously superfused with the normal Tyrode (NT) 
solution. When the cell was impaled with the electrode, action potentials were elicited by a 1Hz 
pulse of up to 3nA current.  
 
2.5.2 Assessing of Ca transients 
2.5.2.1 Fluo-4 AM as the Ca indicator 
    The acetoxymethyl (AM) ester form Ca indicator, Fluo-4 AM, was used to assess intracellular Ca 
changes. Fluo-4 is a non-ratiometric single wavelength calcium probe with an excitation around 490 
nm and emission around 520 nm. The emission intensity represents the level of bound calcium. Fluo-
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4 is an analog of fluo-3 but has a higher quantum yield and provides brighter emission than fluo-3. 
Compared with the other commonly used ratiometric dye, Fura-2, Fluo-4 has a lower Ca affinity (Kd = 
345 nM) than Fura-2 (Kd = 140 nM), which makes Fluo-4 suitable for use in measuring larger Ca 
changes  but not in measuring small changes or the resting Ca level
236
. After following a calibration 
procedure, the ratiometric dye can measure the intracellular Ca concentration more quantitatively 
than Fluo-4. It is difficult to use Fluo-4 quantitatively because its single wavelength excitation and 
emission characteristics cannot account for its intracellular loading.  Qualitative assessments of 
intracellular Ca changes using Fluo-4 are expressed as the ratio F/F0, where the fluorescence level F 
is normalized to the diastolic baseline fluorescence level F0. 
    The acetoxymethyl ester modification of Fluo-4 allows it to penetrate the cell membrane. 
Thereafter intracellular esterases cleave the AM group (de-easterification) leaving the free form of 
Fluo-4 inside the cell and able to bind Ca
237,238
.  
2.5.2.2 Loading of Fluo-4 AM 
    A stock solution of Fluo-4 contained 50μL dimethyl sulfoxide (DMSO), 50μg Fluo-4 AM and 20% 
Pluronic F127 (P-3000MP, Invitrogen). Pluronic F-127 is a non-ionic detergent that can assist in 
better dispersion of the nonpolar AM ester in solution and the transfer of the AM-form across the 
cell membrane. 10 μL stock Fluo-4 AM was added to 1 mL of cell suspension (making the final Fluo-4 
AM concentration approximately 10 μM). While the Fluo-4 loading was taking place and thereafter, 
care was taken to protect the cells and dye from light.  The cells were incubated with the dye at 
room temperature for 20 min on a rocking platform. After that, the dye-incubated cell suspension 
was gently centrifuged at 25°C, 300 rpm, for 1 minute. The supernatant was removed and the pellet 
was re-suspended in indicator-free KB solution for 20 minutes to allow time for de-esterification of 
the AM-form leaving free Fluo-4 inside the cells. Then, the dye-loaded cells could be used for 
monitoring Ca transients for up to 2 hours.  After this time the cells had to be re-loaded with dye  
fluo-4 would tend to leak from the cells slowly or lose its response to Ca
237
.  
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2.5.2.3 Protocol for Ca transient assessment 
    Ca transients were monitored using a Nikon inverted microscope and a photomultiplier. Fluo-4 
loaded cells were placed on a laminin-coated glass coverslip that formed the floor of a small 
superfusion chamber.  The chamber was placed on the stage of the microscope. After allowing the 
cells to settle for 5–10 minutes they were superfused with normal Tyrode solution containing 2 mM 
Ca and paced at 1 Hz usually with two platinum wires on each side of the chamber. The wires were 
connected to an electrical stimulator (Myopacer 100, IonOptix Inc.). A 40x oil immersion lens (Nikon 
Fluor, NA=1.30) was used to view the cells at a high magnification and, using a video monitor, a 
variable aperture mask was manipulated to obscure the area around the chosen cell so that cell 
debris and other cells would not contaminate the light signal coming from the cell under 
investigation. Excitation light (at 485 nm) was provided by a xenon arc lamp. The light emitted by 
Fluo-4 was filtered by a 515 nm bandpass filter (Nikon DM-510) and passed through to the 
photomultiplier. The emitted light produced a current at the photomultiplier that was directly 
proportional to its brightness (Figure 2-4).  The experimental environment was kept as dark as 
possible to eliminate the background noise that other light source might cause. This current from 
the photomultiplier was converted to a voltage that was digitized with an Axon Digidata 1440A and 
recorded using pClamp software. Action potentials were often recorded concomitantly.  
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Figure 2-4. Intracellular calcium measurement with a fluorescence inverted microscope. 
Excitation light from a xenon arc lamp is filtered by a 485 nm excitation filter. The emitted signal 
from Fluo-4 is filtered by a 515 nm emission filter and received by the photomultiplier. 
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2.5.3 Measurements of sarcoplasmic reticulum Ca content 
    Cells were superfused with NT solution and capacitance was measured by using the in-built 
measurement system in pClamp 10.  This involves measuring the integral of the current changes 
occurring in response to 20 ms voltage steps of 5 mV from a holding potential of -80mV. Once cell 
capacitance was noted the cells were stimulated at 1 Hz for 60 s. Once steady-state cell contractions 
were achieved to ensure adequate Ca loading of the SR, stimulation was interrupted and the cells 
were voltage-clamped at -80 mV. The superfusate was rapidly changed to the NT solution containing 
20 mM caffeine. Rapid and continuous application of caffeine increases the open probability of the 
RyRs and causes a maintained release of Ca through the RyRs
239
. Although the SERCA function is not 
inhibited, the decline of the caffeine-induced Ca transient is mainly due to Ca removal via the Na/Ca 
exchanger rather than SR reuptake, which is essentially bypassed
61
. The decline can be used as a 
measure of Na/Ca exchanger function
61
 and quantitative measurements of SR Ca content can be 
made by recording and integrating the inward (Na/Ca exchange) current induced by the rapid 
application of caffeine. The technique and caveats for this method have been described in 
detail
64,71,172,233,240
. 
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2.6 Measurements of Na/K ATPase current  
    Na/K ATPase current was measured in cells voltage-clamped at -80 mV which is usually the resting 
membrane potential of a ventricular myocytes. Capacitance was measured as above. Then a train of 
preconditioning pulses (square clamp pulses from -80mV to 0 mV for 300 ms at a frequency of 1Hz) 
were applied to ensure steady-state cytoplasmic [Na] had been reached. Stimulation was stopped 
and superfusate was switched to the zero-Ca, zero-K superfusate containing 2 mM Ba and 5 mM Ni, 
where Ba was used to block K channels and Ni was used to block Ca channels and NCX. After 60 s, 5 
μM dihydro-ouabain was applied to inhibit the high affinity component of the Na/K ATPase and after 
a further 60 s, 500 μM strophanthidin was applied to produce complete inhibition of the current so 
allowing measurement of total pump current and that due to the individual isoforms of the Na/K 
ATPase
241,242
.  
 
 
 
 
 
 
 
 
 Methods 
 
59 
 
2.7 Immunocytochemical staining of Na/K ATPase α1 and α2 
isoforms 
2.7.1 Immunocytochemical staining  
    Immunocytochemical staining is based on the immune reaction between the antigen and the 
antibody, where the antigen can be a specific protein (in this study are Na/K ATPase α1 and α2 
isoforms), and the antibody to this specific protein is usually conjugated to a fluorophore allowing 
visualization and localization under fluorescence or confocal microscope
243
. There are direct and 
indirect methods for the immunocytochemical staining. The direct method uses a labelled antibody 
to bind the target antigen (e.g. protein) directly. It is simple but less sensitive because there is less 
amplified signal. In contrast, the indirect method contains two steps involving the binding of a 
primary and then a secondary antibody, where the secondary antibody is raised against the IgG of 
the species that the primary antibody comes from. The primary antibody firstly binds to the target 
antigen and then several secondary antibodies with fluorescent label bind to the IgG of the primary 
antibody thus amplifying the signal for detection
243
.  
    The choice of the antibodies is an important issue for a successful Immunocytochemical staining. 
When choosing the primary antibody, one raised from a different species is essential because there 
is less cross-reactivity occurring from endogenous immunoglobulins of the sample cell. In this study, 
we used rabbit anti-sodium pump α1 and α2 isoforms antibodies to probe the α1 and α2 isoforms in 
GP cells. Then the fluorescently conjugated secondary antibody needs to be raised against the same 
specie as the primary antibody been raised from. In this study, we used goat anti-rabbit IgG antibody 
that is conjugated with Alexa Fluor® 488. 
    In most circumstance, the detergent such as Triton X-100 is used for a better penetration of 
antibody to bind the subcellular proteins. Triton-X 100 is a nonionic detergent that can break 
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protein-lipid and lipid-lipid associations but does not denature proteins. This facilitates the entry of 
antibodies into the cell without influencing the properties of the target proteins
244
.  
 
2.7.2 Confocal microscopy imaging 
    Minsky invented the confocal microscope in 1957 to improve the problems of resolution and 
contrast of the traditional wide-filed fluorescence microscope caused by a large background noise 
from unfocused areas
245
. His confocal concept consists of point illumination and a conjugated 
pinhole plane in front of the photomultiplier detector (Figure 2-5). This conjugated pinhole plane 
only allows the in-focus light rays emitted from nearly the same focal plane to pass thus creating 
thin optical sections from thick specimens and allowing imaging deep into light scattering samples.  
The final images are much clearer than those obtained with a wide-field microscope. However, 
because only very limited density of in-focus light rays can pass the pinhole, acquiring the images 
needs longer exposure times.    
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Figure 2-5. Immunocytochemical fluorescence imaging with an inverted confocal laser scanning 
microscope.  
The excitation light is provided by an argon laser and then filtered by a pinhole plate  and an 
excitation filter. The filtered light is reflected by a dichronic mirror and  goes through the oil 
immersion lens to the sample. The emitted light is filtered by a fluorescence barrier filter and a 
detector pinhole plate, which excludes out-of-focus light rays. The in-focus light rays are detected by 
the photomultiplier detector.  
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2.7.3 Materials 
    1. 35 mm petri dish with a 14 mm microwell and no. 0 coverglass (MatTek). 
    2. Laminin (natural mouse, gibco® by Life Technologies™).  
    3. Phosphate buffer saline (PBS), 1 tablet (Fisher Chemical) in the purified water to make 200 ml   
        stock to be used on the day of experiment. 
    4. 4 % paraformaldehyde (PFA, Sigma-Aldrich) solution in PBS. 
    5. Permeabilization agent: 0.05% TritonX-100 in PBS. 
    6. Blocking solution: 2-4 % bovine serum albumin (BSA) in PBS + Goat serum (2-3 %). 
    7. Antibody solution: 50% blocking solution in PBS. 
    8. Primary antibodies:  
      a. Rabbit anti-sodium pump α-1 polyclonal antibody (Millipore), stored at -20°C, use at a  
          dilution of 1:200 in antibody solution.  
     b. Rabbit anti-sodium pump α-2 polyclonal antibody (Millipore), stored at -20°C, use at a  
         dilution of 1:150 in antibody solution. 
    9. Secondary antibodies: Alexa Fluor® 488 goat anti-rabbit IgG (H+L) 2mg/mL (molecular probes®  
         by Life Technologies™), stored at -20°C, use at a dilution of 1:500.  
   10. Vectashield® mounting medium for fluorescence with 4',6-diamidino-2-phenylindole (DAPI)  
         (Vector Laboratories Inc.), stored at 4°C.  
    11. Zeiss LSM780 confocal microscope (Carl Zeiss Microscopy GmbH) with Argon laser. 
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2.7.4 Protocol 
    Enzymatically isolated cardiomyocytes were firmly stuck with laminin (natural mouse, Gibco) to 
glass bottom culture dishes (35 mm petri dish, 14 mm microwell with No. 0 coverglass, MatTek).  
Myocytes were washed quickly with phosphate buffer saline (PBS, 100mg tablet dissolved in purified 
water to 100ml, Sigma) 3 times (0.5 ml/chamber) and then fixed with 4% paraformaldehyde (PFA) 
for 10 minutes. Triton-X detergent (0.05% in PBS) was then used to permeablize cardiomyocytes to 
facilitate the penetration of antibodies. Non-specific antibody binding sites were blocked with 
“blocking solution” (2-4 % bovine serum albumin (BSA) + 2-3% goat serum in PBS) applied for 30 
minutes. The above procedures were carried out at room temperature.  
    Dissolved primary antibody (Rabbit anti-Na/K ATPase α-1 (Millipore, 06-520) at a dilution of 1:200 
and Rabbit anti-Na/K ATPase α-2 (Millipore, AB9094) at a dilution of 1:150) in antibody solution 
(blocking solution + PBS, 50:50) was added into the culture dish. Incubation of the cells with 
antibody was done overnight at 4°C. After over 12 hours of incubation, cardiomyocytes were washed 
3 times with PBS for 5 minutes duration each time. An Alexa Fluor® 488 conjugated secondary 
antibody (Alexa Fluor® 488 goat anti-rabbit IgG (H+L) 2mg/mL (Molecular Probes® by Life 
Technologies™)) was diluted 1:500, applied to the cells and incubated for 3 hours. After washing 
cells with PBS twice (5 min duration each), the cardiomyocytes were finally mounted by 1 drop of 
Vectashield® (Vector Laboratories Inc.) mounting medium for fluorescence with 4', 6-diamidino-2-
phenylindole (DAPI), which is a fluorescent dye that can penetrate the cell membrane and bind 
strongly to the A-T (adenine and thymine) rich region of DNA thus indicating the nucleus as blue (its 
maximum emission wavelength is 461nm) under confocal microscopy
246
. The petri dishes were 
covered with foil to protect them from light and were ready for image acquisition with a Zeiss 
LSM780 confocal microscope.  During the above procedure, great care was taken to minimize loss of 
myocytes, (not allowing the cardiomyocytes to be dry for longer than 2 seconds at a time and, 
between washing, examining the attachment of the cardiomyocytes with a microscope to make sure 
they remained adherent). 
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2.8 Wheat germ agglutinin membrane staining 
2.8.1 Wheat germ agglutinin 
    Wheat germ agglutinin (WGA) is a lectin that protects wheat from insects, yeast and bacteria. It 
selectively binds to N‑acetylglucosamine and N‑acetylneuraminic acid (sialic acid) residues in the 
cell membrane
247
. WGA has been used extensively to stain surface membranes, including t-tubules 
in cardiac myocytes
216,248
. This study used Alexa Fluo® 594 conjugated WGA (Invitrogen by life 
Technologies™) as a membrane staining that emits as an orange-red color. 
 
2.8.2 Materials 
1. 35 mm petri dish with a 14 mm microwell and no. 0 coverglass (MatTek). 
2. Laminin (natural mouse, gibco® by Life Technologies™).  
3. Phosphate buffer saline (PBS), 1 tablet (Fisher Chemical) in 200 ml the purified water. 
4. 4 % paraformaldehyde (PFA, Sigma-Aldrich) solution in PBS. 
5. Wheat germ agglutinin (Alexa Fluor® 594 conjugated WGA, Invitrogen by life   
      Technologies™), stored at -20°C. 
6. Vectashield® mounting medium for fluorescence with DAPI (Vector Laboratories Inc.), stored    
      at 4°C.  
7. Zeiss LSM780 confocal microscope (Carl Zeiss Microscopy GmbH) with Argon laser. 
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2.8.3 Protocol 
    Enzymatic isolation of cardiac myocytes was performed using the protocol described before. 
Myocytes were stuck to glass bottom culture dish with laminin. Then they were washed quickly with 
phosphate buffer saline (PBS) 3 times followed by fixing with 4% paraformaldehyde (PFA) for 10 
minutes. Finally myocytes were incubated with Alexa Fluo® 594 conjugated WGA (at a concentration 
of 100 μg/mL) for 1 hour. The above procedures were carried out at room temperature. In some 
experiments, WGA staining was performed concomitantly with immunocytochemical staining of 
Na/K ATPase α1 and α2 isoforms. Therefore in these experiments, WGA conjugated Alexa Fluo® 594 
dye was added before the step of staining with primary antibody as described in section 2.7.4. 
    Confocal images were obtained with a Zeiss LSM780 confocal microscope and processed by the 
software Zen© (Carl Zeiss Microscopy GmbH, 2011). Average fluorescence density was measured 
using the software ImageJ (NIH, USA) with longitudinal linear measurements indicating distribution 
of t-tubules and a fixed range of interest (ROI) providing an index of t-tubule density. Spatial 
frequency analysis of t-tubules arrangement was performed with MatLab® software (The 
MathWorks® Inc.). 
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2.9 Solutions for experiments 
    The composition of solutions used for all experiments are listed below in mM. The pH was 
adjusted at room temperature. Chemicals were purchased from Sigma-Aldrich Company Ltd., Poole, 
Dorset, UK.  
2.9.1 Normal Tyrode solution 
NaCl  140; KCl  6; MgCl2  1; CaCl2  2; glucose  10; N-2-hydroxyethylpiperazine-N’-2-ethanesulphonic 
acid (HEPES)  10; pH adjusted to 7.40 with NaOH. 
2.9.2 Low Ca solution 
NaCl  120; KCl  5.4; MgSO4  5; Na pyruvate  5; glucose  20; taurine  20; HEPES  10; nitrilotriacetic acid 
(NTA)  5; CaCl2  35 μM; pH adjusted to 6.96 with NaOH. 
2.9.3 Enzyme solution 
NaCl  120; KCl  5.4; MgSO4  5; Na Pyruvate  5; glucose  20; taurine  20; HEPES  10; CaCl2  200 μM; pH 
adjusted to 7.40 with NaOH. 
2.9.4 Kraft-Bruhe (KB) solution 
NaCl  15; KCl  85; glucose  20; KH2PO4  30; MgSO4  5; taurine  20; NTA  0.5; Na pyruvate  5; β-
hydroxybutyric acid  5; creatine  5; pH adjusted to 7.20 with KOH. 
2.9.5 Caffeine solution 
NaCl  140; KCl  6; MgCl2  1; CaCl2  2; glucose  10; HEPES  10; caffeine 20; pH adjusted to 7.40 with 
NaOH. 
2.9.6 Zero Na, zero Ca solution 
LiCl  140; KCl  6; MgCl2  1; EGTA  1; glucose  10; HEPES  10; pH adjusted to 7.40 with LiOH. 
2.9.7 Micropipette filling solution 
KCl  2M; HEPES  10; EGTA 100μM; pH adjusted to 7.20 with KOH. 
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2.10 Statistical analysis 
Data handling, processing, statistical analysis, and the graph production were performed with 
Microsoft Excel 2010 (Microsoft Corporation, Redmond, WA, USA) and with GraphPad Prism ver. 4.0 
(GraphPad Software Inc., San Diego, CA, USA). CorelDRAW ver. X5 (Corel Systems Corp., Ottawa, 
Canada) was used to present graphs and traces. 
Results are expressed as mean ± SEM. Student’s t test using GraphPad Prism ver. 4.0 (GraphPad 
Software Inc., San Diego, CA, USA) was used to assess statistical differences between the sham and 
AC groups with a p-value less than 0.05 taken as indicating a significant difference between means. A 
one-way ANOVA with Tukey's multiple comparison test was used to examine the variances among 
the AC groups at three time points. A p-value less than 0.05 indicated significance. Two-way ANOVA 
with Bonferroni post-test was used to examine the results of Na/K ATPase high and low ouabain-
affinity currents between the sham and AC groups at different time points. A p-value less than 0.05 
indicated significance.   
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3 PROGRESSION OF HYPERTROPHY TOWARD HEART FAILURE 
 Progression of hypertrophy toward heart failure 
 
69 
 
3.1 Introduction 
    In the past decades, physicians and scientists have tried to establish mechanisms and models for 
progression of heart failure. However, no single mechanism or model could define the syndrome of 
heart failure well, because the presentation of heart failure is a combination of multiple alterations 
in functional and biological aspects. Packer proposed a neurohumoral hypothesis to explain the 
mechanism of progression of heart failure in 1992
249
 and against the traditional haemodynamic 
hypothesis that merely explained the symptoms of HF. He tried to block the effects of neurohumoral 
systems, such as sympathetic nervous and renin-angiotensin systems, and found some benefits in 
morbidity and mortality that could not be provided by therapy targeted on contractility and ejection 
fraction. Mann proposed a hypothesis involving cardiorenal, haemodynamic and neurohumoral 
aspects to describe heart failure and therapeutic strategies aimed at alleviating the symptoms
145
. 
However, he also pointed out that heart failure is a progressive disease, which could not be fully 
explained by one single pathophysiological model. Understanding the underlying mechanisms that 
alter the progression might be the way to intervene in the development of heart failure and even 
reverse it.  
    Since heart failure refers to a consequence of disease progression, the related symptoms and signs 
are used to diagnose and determine the grade of disease. Clinically in human, history taking, physical 
examination, followed by laboratory examination provide parameters for disease diagnosis and 
progression. Table 3-1 is a list of commonly used criteria to classify the grade of heart failure 
according to symptoms: The New York Heart Association (NYHA) Functional Classification
250
.  
Laboratory examinations, including a B-type natriuretic peptide (BNP) blood test, chest radiography, 
electrocardiography (ECG), and echocardiography, provide objective parameters to diagnose and 
evaluate heart failure. However, in animals, subjective history taking is not applicable. Objective 
observations of heart failure signs combined with echocardiography examination provide useful 
parameters to monitor disease progression in our guinea-pig model of progressive heart failure. 
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Table 3-1. The New York Heart Association (NYHA) Functional Classification.  
From The Criteria Committee of the New York Heart Association. (1994). Nomenclature and Criteria 
for Diagnosis of Diseases of the Heart and Great Vessels. (9th ed.). Boston: Little, Brown & Co. pp. 
253–256. 
 
NYHA 
Class 
Symptoms 
I 
Cardiac disease, but no symptoms and no limitation in ordinary physical activity, e.g. 
shortness of breath when walking, climbing stairs etc. 
II 
Mild symptoms (mild shortness of breath and/or angina) and slight limitation during 
ordinary activity. 
III 
Marked limitation in activity due to symptoms, even during less-than-ordinary activity, 
e.g. walking short distances (20–100 m). 
Comfortable only at rest. 
IV 
Severe limitations. Experiences symptoms even while at rest. Mostly bedbound 
patients. 
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3.2 Functional classification of guinea pigs 
    In our guinea-pig progressive heart failure model, we monitored the post-operative conditions of 
animals according to The New York Heart Association (NYHA) Functional Classification (table 3-1). At 
30 days after operation, no significant signs of heart failure could be noted in both sham and AC 
groups. At 60 days after aortic constriction, most GPs in the AC group had no signs of heart failure or 
limitation of daily activity, although some of them were found to have temporarily poor appetite or 
shortness of breath. Because we knew that they had cardiac dysfunction (created by us), we could 
classify the GPs at this stage as NYHA functional class (Fc) I-II. When the experiment came close to 
the end point of 150 days after the TAC operation, most of the GPs in the AC group showed signs of 
heart failure such as dyspnea, poor appetite, cyanosis of extremities, and decreased or limited 
activity. Referring to the criteria, NYHA Fc III-IV was confirmed at this end stage. Besides, five GPs in 
the AC group were found dead suddenly during 60 to 150 days after operation, which might have 
been due to arrhythmia.  
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3.3 Echocardiography for heart function examination 
Echocardiography is an useful, non-invasive tool to evaluate cardiac function and monitor the 
morphological changes of the heart during the progression of heart failure.   
M-mode echocardiography was performed on unanaesthetized GPs at pre-operation, 30, 60, 90, 
120, and 150 days after operation to determine the in vivo cardiac function without the 
complications of anaesthesia during the progression of disease.  
 
3.3.1 Methods 
Echocardiography was performed to measure the left ventricular internal diameter in diastole 
(LVIDd) and systole (LVIDs), then the FS was calculated with the equation: 
FS =    
	

    
by the pre-set function built into the echo machine. The whole procedure was tape-recorded for 
future analysis. A typical recording is shown in Figure 2-2.  
    Measurement of thickness of ventricular wall was attempted, however, the resolution of images 
was poor due to post-operative adhesion of soft tissue surrounding the heart causing technical 
limitations. 
 
3.3.2 Result of echocardiography 
3.3.2.1 Fractional shortening 
Figure 3-1 shows the fractional shortening (FS) measured prior to the operation and then 30, 60, 
90, 120, and 150 days thereafter in sham and TAC (AC) groups.  There is no difference between sham 
and AC groups prior to the operation (67.0 ± 2.4%, N=19, in the sham group and 63.6 ± 1.1%, N=39, 
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in the AC group, Student’s t-test, p=0.143 Figure 3-1 A).  Figure 3-1 B shows that there is a significant 
decrease of FS in the AC group 30 days after the operation, which indicates the successful effect of 
the surgical procedure.  FS declines from 65.7 ± 1.8%, N=11, in the sham group to 55.5 ± 2.1%, N=16, 
in the AC group (Student’s t-test, **p=0.002).  Figures 3-1 C and D show no significant difference in 
the FS between sham and AC groups at 60 days (64.5 ± 6.4%, N=7, in the sham group and 53.0 ± 
4.3%, N=9, in the AC group, Student’s t-test, p=0.146) and 90 days after the operation (65.5 ± 3.5%, 
N=9, in the sham group and 56.1 ± 3.9%, N=9, in the AC group, Student’s t-test, p=0.089).  The 
results suggest that during this period there has been development of compensatory hypertrophy to 
preserve contractile function. At 120 and 150 days after the operation (Figure 3-1 E and F), heart 
function becomes much poorer and the earlier compensation is lost. FS decreases (at 120 days from 
62.2 ± 2.4%, N=10, in the sham group to 48.1 ± 5.0%, N=8, in the AC group, Student’s t-test, 
*p=0.016; and at 150 days from 70.0 ± 3.3%, N=9, in the sham group to 39.1 ± 2.4%, N=11, in the AC 
group, Student’s t-test, ***p<0.001). 
Figure 3-2 shows the progressive decrease in FS in the AC group from pre-operation to 150 days 
postoperatively. In panel A, at 30 days after operation, a significant decrease in FS is noted (ANOVA 
with Tukey’s multiple comparison test, *p<0.05). During 30 days to 90 days after aortic constriction, 
FS shows no significant difference between different time points, indicating a compensation of 
contractile function during this period. The FS decreases 120 days after AC and shows a significant 
difference at the 150 day end point (ANOVA with Tukey’s multiple comparison test, ***p<0.001). 
These results indicate that our surgical aortic constriction has created a successful animal model of 
hypertrophy progression toward heart failure. In panel B, FS at each time point is normalized to the 
pre-operative FS. FS decreases by about 15% at 30 days after the operation and enters a “plateau” 
period between 30 and 90 days. After 120 days, FS declines and then progresses to the 150 days end 
point, at which point there is around a 40% decrease compared with  the pre-operative FS. 
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Figure 3-1. Echocardiography examination of fractional shortening (FS) in sham and AC groups 
at different time points following the AC operation noted above each individual panel. (N= 
numbers of animals. 
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Figure 3-2. Mean fractional shortening changes in the AC group.   
Panel A indicates that FS decreases firstly at 30 days after the AC operation (ANOVA with Tukey’s 
multiple comparison test, *p<0.05), which confirms effective aortic constriction causing a change to 
heart function. Between 30 and 90 days after the operation, the fractional shortening does not 
decrease but is stable (circled, Tukey’s multiple comparison test, p>0.05). FS declines at 120 days 
post AC with a further decrease at 150 days post AC (Tukey’s multiple comparison test, 
***p<0.001). Panel B presents the mean FS changes normalized to illustrate the progression of 
decline in FS. 
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3.3.2.2 Left ventricular internal diameter in systole and diastole 
Figure 3-3 shows the changes in left ventricular internal diameter in systole (LVIDs) prior to the 
operation and 30, 60, 90, 120, and 150 days thereafter. Pre-operative evaluation shows no 
significant difference between sham and AC groups (Figure 3-3 A), 0.19 ± 0.02cm, N=10, in the sham 
group and 0.19 ± 0.01cm, N=56, in the AC group, Student’s t-test, p=0.755). 30 days after aortic 
constriction (Figure 3-3 B), there is a significant increase in LVIDs (0.22 ± 0.02cm, N=7, in the sham 
group and 0.30 ± 0.02cm, N=17, in the AC group, Student’s t-test, **p=0.01). Data collected at 60, 90, 
and 120 days after the operation (Figure 3-3 C, D, and E) show no significant difference between 
sham and AC groups. At the 150 day end point, LVIDs in the AC group have  increased (from 0.18 ± 
0.01cm, N=5, in the sham group to  0.50 ± 0.03cm, N=11, in the AC group, Student’s t-test, 
***p<0.001), which suggests that pump contractility is beginning to be severely limited and implies a 
possible decompensation of the initial response to the AC. 
Figure 3-4 indicates changes to another echocardiographic parameter, left ventricular internal 
diameter in diastole (LVIDd), during the post-operative period up to 150 days. There is no significant 
difference between sham and AV groups at pre-operational evaluation (0.55 ± 0.04cm, N=10, in the 
sham group and 0.53 ± 0.01cm, N=56, in the AC group, Student’s t-test, p=0.446). 30 days after the 
operation, in contrast to the LVIDs result, LVIDd remains similar in both groups (0.61 ± 0.02cm, N=7, 
in the sham group and 0.65 ± 0.02cm, N=17, in the AC group, Student’s t-test, p=0.282). The LVIDd  is 
stable until 150 days after aortic constriction, when it mirrors the poor systolic function at 150 days, 
0.66 ± 0.03cm, N=8, in the sham group and 0.79 ± 0.03cm, N=12, in the AC group, Student’s t-test, 
**p=0.006). 
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Figure 3-3. Echocardiography examination of the left ventricular diameter in systole (LVIDs). A 
comparison between sham and AC groups at different time points.  
Significant decrease of LVIDs at 30 days after operation (B) confirms the success of the aortic 
constriction by causing an increase in LVID.  There is no difference between sham and AC groups at 60, 
90, and 120 days after the operation (C, D, and E). A significant increase in LVIDs occurs at 150 days 
post operation (F).N= numbers of animals. 
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 Figure 3-4. Echocardiography examination of left ventricular diameter in diastole (LVIDd). A 
comparison between sham and AC groups at different time points.  
A significant increase of LVIDd is shown at 150 days post operation (F). N= numbers of animals. 
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3.4 Biophysiological changes during the progression of disease 
Clinically, in human, some biophysical parameters, such as abdominal edema, peripheral edema, 
and exertional dyspnea, can be used to determine the degree of disease progression. However, 
these indices of disease progression are not easily applicable to our guinea-pigs. Instead, alternative 
indices, heart weight (HW, g) / body weight (BW, Kg) and lung weight (LW, g) / body weight (BW, Kg) 
ratios were obtained to indicate the biophysiological changes occurring during progression towards 
deleterious heart function in our animal model. 
After the heart and lungs were removed, they were put into a pre-weighted specimen jars of cold 
and heparinized NT solution (formula please see chapter 2.7). The weights of heart and lungs were 
measured respectively and the ratios of HW / BW and LW / BW were calculated and used as indices 
of progression of hypertrophy toward heart failure. 
 
3.4.1 Heart weight / Body weight and Lung weight/ Body weight results 
    Table 3-2 indicates body weight, heart weight, and lung weight data at various timepoints in the 
sham and AC groups. Body weights in both groups increase along with the normal growth. However, 
the body weight in the AC group at 60 days after AC is significantly lighter than that in the sham 
group, perhaps indicating that the increased working load of the heart has influenced the growth. At 
the 150 day end point, both groups have comparable body weights. The slower increase of the body 
weight in the AC group might indicate fluid retention because heart failure occurs at this stage. The 
heart weights in the AC group are significantly heavier than those in the sham group 60 days after 
the operation, which indicates AC-induced cardiac hypertrophy. The lung weights are not 
significantly different between the sham and AC groups until the 150 day end point, when the lung 
weight in the AC group is significantly heavier than that in the sham group indicating pulmonary 
congestion when the heart fails. 
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Figure 3-5 shows HW/BW ratios at the various timepoints. At 30 days after the operation, the 
ratio is 3.97 ± 0.1, N=9, in the sham group and 5.14 ± 0.54, N=6, in the AC group (Student’s t-test, 
*p=0.021). At 60 days post operation, the ratio increases significantly in the AC group (3.51 ± 0.08, 
N=14, in the sham group and 5.20 ± 0.20, N=11, in the AC group, Student’s t-test, ***p<0.001), 
indicating the development of hypertrophy of the heart to compete against the increased aortic 
pressure and preserve an adequate cardiac ejection function. At 150 days after the operation, the 
ratio still shows a significant difference between the sham and AC groups (3.45 ± 0.11, N=20, in the 
sham group and 4.80 ± 0.30, N=16, in the AC group, Student’s t-test, ***p<0.001). 
Figure 3-6 shows LW/BW data collected at the same time points. There is no significant difference 
between sham and AC groups until 60 days after the operation. At this timepoint the ratio in the AC 
group is significantly higher than in the sham group (4.88 ± 0.12, N=15, in the sham group and 7.08 ± 
1.03, N=11, on the AC group, Student’s t-test, *p=0.021). At 150 days after the operation, the ratio 
still shows a significant difference between the sham and AC groups (4.58 ± 0.15, N=20, in the sham 
group and 6.90 ± 0.80, N=16, in the AC group, Student’s t-test, **p=0.003.). 
    Figure 3-7 indicates the progressive changes in HW (A) and LW (B) at 30, 60, and 150 days in the 
animals with aortic constriction. Heart weight increases significantly from 30 days to 60 days after 
operation (3.50 ± 0.26g, N=6, at 30 days and 4.62 ± 0.22g, N=11, at 60 days, Tukey’s multiple 
comparison test, *p<0.05). There is no significant difference between 60 days to 150 days after AC 
although the HW keeps increasing during the progression (4.62 ± 0.22g, N=11, at 60 days and 4.94 ± 
0.23g, N=16, at 150 days, Tukey’s multiple comparison test, p>0.05). However, the HW at 150 days 
comparing to that at 30 days after the AC operation is significantly increased (Tukey’s multiple 
comparison test, **p<0.01). The lung weight keeps increasing over the same time points, although 
no statistical difference is noted between sequential time points (at 30 days, 5.08 ± 1.19g, N=6; at 60 
days, 6.42 ± 1.07g, N=11, p=0.440; at 150 days, 6.92 ± 0.56g, N=16, one-way ANOVA, p=0.409).     
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 Sham AC P value 
Body weight (g)    
30 days 768.6 ± 22.0 700.9 ± 52.3 0.199 
60 days  1035 ± 32.3 890.4 ± 29.9 0.004** 
150 days 1149 ± 28.6 1057 ± 45.8 0.086 
    
Heart weight (g)    
30 days 3.04 ± 0.06 3.50 ± 0.26 0.054 
60 days  3.72 ± 0.09 4.62 ± 0.22 <0.001*** 
150 days 3.93 ± 0.11 4.94 ± 0.23 <0.001*** 
    
Lung weight (g)    
30 days 4.56 ± 0.20 5.08 ± 1.19 0.610 
60 days  5.03 ± 0.15 6.42 ± 1.07 0.145 
150 days 5.23 ± 0.18 6.92 ± 0.56 0.004** 
 
Table 3-2. Changes of body weight, heart weight, and lung weight after sham and AC operation. 
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Figure 3-5. Heart weight (g)/ Body weight (Kg) at 30, 60, and 150 days after operation.  
The ratio increases significantly at 30 days after the AC operation and remains high. N= 
numbers of animals. 
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Figure 3-6. Lung weight (g)/ Body weight (Kg) at 30, 60, and 150 days after operation.  
The ratio is not significantly different between the sham and AC groups until 120 days 
after the operation. N= numbers of animals. 
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Figure 3-7. Heart weight (A) and lung weight (B) changes in AC groups at 30, 60, and 150 days after the 
operation.  
In panel A, the heart weight increases significantly from 30 days to 60 days (Tukey’s multiple comparison, 
*p<0.05). At 150 days the HW is greatest. In panel B, there is no statistical difference between sequential 
time points. 
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3.5 Discussion 
    Since heart failure is the result of a progressive decline of cardiac performance, we use functional 
criteria and physiological data obtained by echocardiography examination and heart and lung weight 
(usually expressed as a ratio with body weight) to determine the stage of heart function. The final 
result confirms that our animal model successfully reproduces many aspects of progressive heart 
failure.  
    Fractional shortening (FS) reveals the contractility of heart, which determines the pumping 
function to support the whole body circulation. Parameters used to calculate FS are left ventricular 
internal diameter in systole and diastole (LVIDs and LVIDd).  
    FS measured at 30 days after aortic constriction is significantly lower than in the sham group, 
which indicates that our aortic constriction has made the aortic pressure higher. We confirm this 
effect by the corresponding increase of LVIDs. In other words, the contractile power is not able to 
compensate for the increased aortic pressure completely at this stage. On the other hand, the LVIDd 
remains unchanged, which means the relaxation of heart is not affected. The heart weight / body 
weight ratio indicates there is a proportional increase in cardiac muscle mass. The lung weight / 
body weight ratios are not different between sham and AC groups at this stage, probably reflecting 
that the increased afterload is only affecting the function of the left heart and not the right heart yet. 
Clearly the left side heart function is still meeting the demands of the circulation and the animals do 
not present with any signs of heart failure.  
    After this period, the contractile function remains balanced at 60 days post operatively. FS, LVIDs, 
and LVIDd data show no significant difference between the sham and AC groups. However, the heart 
weight / body weight ratio is increasing in the AC group. Although the internal diameters of left 
ventricle in systole or diastole do not change, the thickness of ventricular wall has increased because 
the heart weight has increased. These data reveal a compensation status has been established with 
the hypertrophy of cardiac muscle. Again, at this stage, most GPs did not show clinical signs of heart 
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failure, although some of them experienced temporary poor appetite and occasional shortness of 
breath. NYHA Fc I-II could be considered and evidence suggests these animals have a form of 
compensated cardiac hypertrophy. 
    After this stage until the 150 day end point, more GPs showed signs of heart failure, such as poor 
food intake, dyspnea, decreased movement, and cyanosis of extremities, in different degrees. These 
signs could be considered as NYHA Fc III-IV. Five of the animals suffered sudden death most likely 
caused by arrhythmia, also a common cause of death in heart failure patients. At 150 days after the 
AC operation, the destination point of our experiment, the FS drops significantly with larger LVIDs 
and LVIDd. The large decline in FS means the pumping function is greatly reduced and cannot 
maintain a sufficient circulation, which causes the observed signs of heart failure. Enlarged LVIDs and 
LVIDd confirm the morphology change with chamber dilatation at end stage heart failure. The 
enlargement of LVIDs in the AC group indicates poor contraction of the left ventricle. The enlarged 
LVIDd shows severe blood retention in the left ventricle. This would cause a retrograde effect and 
produce pulmonary congestion and right side heart failure, which could be confirmed by the 
increased lung weight / body weight ratio at this stage. Furthermore, when we dissected GPs to 
harvest hearts for experiments, we noticed large ascites, congested and enlarged livers, and pleural 
effusion combined with congested lungs. All these lines of evidence confirm the status of end stage 
heart failure.  
    According to the findings described above, the progression of heart failure in aortic constricted 
GPs is similar to the progression of disease in human although presumably on a different time-scale. 
At 30 days after AC, there is a decrease in heart function without clinical signs being observed. At 60 
days after AC, compensated hypertrophy is confirmed by increased cardiac muscle mass with 
acceptable contractile function, but without significant morphology changes. At the 150 day end 
point, decompensated end stage heart failure is considered due to severe heart failure signs, poor 
contractile function, large changes in cardiac morphology, and whole body circulatory insufficiency. 
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We can confirm this is a successful animal model of progressive heart failure in guinea-pigs. For a 
more thorough evaluation of heart failure progression, gold-standard biomarkers such as B-type 
natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP), and novel potential biomarkers such 
as mid-regional pro atrial natriuretic peptide (MR-proANP), mid-regional pro adrenomedullin (MR-
proADM), highly sensitive troponins, soluble ST2 (sST2), growth differentiation factor (GDF)-15 and 
Galectin-3, could be used to provide a more complete analysis in biochemical, histological, and 
neurohormonal aspects
251
.  
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4 ELECTROPHYSIOLOGICAL CHANGES DURING PROGRESSION OF 
HYPERTROPHY TOWARD HEART FAILURE 
 Electrophysiological Changes During Progression of Hypertrophy toward Heart 
Failure 
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4.1 Introduction 
    Alterations to cellular Ca handling can influence E-C coupling and contractile force.  To understand 
the changes of calcium handling mechanisms during the progression of hypertrophy toward heart 
failure, measurements of action potential duration, SR Ca content, Ca transients, and Na/K ATPase 
current were performed. Experiments were carried out on single cardiomyocytes isolated from 
guinea pigs that underwent either sham or AC operation 30, 60, and 150 days earlier.  
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4.2 Isolation of cardiomyocytes 
    Experiments were performed on single cardiomyocytes isolated from the hearts of sham- and AC-
operated GPs as described in Chapter 2.  
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4.3 Action potential duration measurement 
4.3.1 Aim 
The aim of this section of work was to measure and compare the electrical event – the action 
potential – that triggers contraction in cardiac myocytes isolated from AC animals with those from 
sham operated animals to assess what changes in the excitatory process occur during the 
progression of disease. 
 
4.3.2 Method 
    Action potentials were recorded using sharp microelectrodes constructed as described in Chapter 
2. 
 
4.3.3 Results 
    The cells were current-clamped and stimulated at 1 Hz, when steady contraction was reached, 
action potentials were recorded for 30 s, and therefore 30 action potential traces were recorded. 
The average measurements of action potential duration at 90% repolarization (APD90) were made by 
using the averaging facility in pClamp. A typical AP recorded from a ventricular myocytes isolated 
from a GP heart 30 days after a sham operation is shown in Figure 4-1. The mean results for action 
potential duration together with sample recordings are displayed in Figure 4-2. 30 days after the AC 
operation, APD prolongs by 22% in the AC group from a mean of 169 ± 7ms, n=31, in the sham group 
to a mean of 206 ± 9ms, n=22, in the AC group, (Student’s t-test, **p=0.001). 60 days after the AC 
operation, APD is again 21% longer in the AC group compared with the sham group (Student’s t-test, 
***p<0.001) but the mean APDs have both prolonged (from 169 ± 7ms, n=31 at 30 days to 204 ± 
7ms, n=26, at 60 days in the sham group, Tukey’s multiple comparison test, ***p<0.001; from 206 ± 
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9ms, n=22, at 30 days to 247 ± 7ms, n=11, at 60 days in the AC group, Tukey’s multiple comparison 
test, **p<0.01). At the heart failure end point, APD in the AC group is 33% longer (having increased 
from 180 ± 6ms, n=31, in the sham group to 241 ± 11ms, n=11, in the AC group, Student’s t-test, 
***p<0.001).  
The changes of APD in the sham and AC groups at 3 time points are shown in Figure 4-3 
respectively. Although APD prolongation is also noted in the sham group at 60 days after operation 
(Tukey’s multiple comparison test, ***p<0.001), the APD at 150 days after operation is not 
significantly different from mean APD  measured at 30 days after operation (Tukey’s multiple 
comparison test, p>0.05). APD prolongs significantly during the progression of compensated 
hypertrophy at 60 days (Tukey’s multiple comparison test, **p<0.01) (Figure 4-3 B). However, when 
decompensation occurs at 150 days, APD is longer than APD at 30 days (Tukey’s multiple comparison 
test, *p<0.05), but is not different from mean APD measured at 60 days (Tukey’s multiple 
comparison test, p>0.05).  
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Figure 4-1. A typical action potential duration trace recorded on an enzymatically isolated 
ventricular myocytes from a male guinea pig 30 days after sham operation.   
The duration is around 165 ms. Resting membrane potential is about -85 mV. The maximal 
potential reached is about 40 mV. 
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Figure 4-2. Action potential duration measured at 30, 60, and 150 days after operation.  
The prolongation of action potential duration with statistical significance is noted at all 3 time points. 
(n= cell numbers isolated from 3-9 animals)  
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Figure 4-3. Changes in action potential duration over time in the sham (A) and AC 
group (B).  
(n= cell numbers isolated from 3-9 animals) 
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4.4 Measurement of calcium transients  
4.4.1 Aim 
    The aim of this section of work was to measure and compare the Ca transients in cardiac myocytes 
isolated from AC animals with those from sham operated animals to assess what changes in cellular 
Ca handling occurred. 
 
4.4.2 Measurement of Ca transients 
    Ca transients were measured as described in detail in Chapter 2. 
 
4.4.3 Results 
    The mean amplitude of Ca transients 30 days after banding are not different between sham and 
AC groups (Figure 4-5 A, B), (F/F0 = 2.97 ± 0.36, n=6, in the sham group and 3.10 ± 0.14, n=6 in the AC 
group, Student’s t test, p=0.731). As shown in panels C and D in Figure 4-5, myocytes from the AC 
group 60 days after the operation displayed larger amplitudes compared with the sham group (F/F0 
= 3.29 ± 0.29, n=9, in the sham group and 4.02 ± 0.09, n=11, in the AC group, Student’s t test, 
*p=0.017). However, the mean amplitude of the Ca transients at 150 days after operation is 
significantly smaller in the AC group compared with the sham group (Figure 4-5 E and F), (F/F0 = 3.03 
± 0.16, n=10, in the sham group and 1.82 ± 0.11, n=10, in the AC group, Student’s t test, ***p<0.001). 
Therefore the amplitude of the Ca transients increase at 60 days post AC but decrease when heart 
failure develops around 150 days after the AC operation. This time comparison of the amplitudes in 
the sham and AC groups is shown in Figure 4-6. 
    The time to peak (TTP) amplitude of the Ca transient provides some assessment of the efficacy of 
the CICR process.  Mean data are shown in Figure 4-7. There is no significant difference between the 
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mean TTP values measured in the sham and the AC groups at 30 and 60 days after the operation (at 
30 days, TTP = 69 ± 9 ms, n=6, in the sham group and 71 ± 9 ms, n=6, in the AC group, Student’s t-
test, p=0.883; at 60 days, TTP = 80 ± 7 ms, n=9, in the sham group and 84 ± 11 ms, n=11, in the AC 
group, Student’s t-test, p=0.755).  The TTP becomes prolonged in the AC group at the 150 day end 
point compared with the sham group (73 ± 2 ms, n=10, in the sham group and 83 ± 2 ms, n=10, in 
the AC group, Student’s t-test, **p=0.008). 
    The time from the peak of the transient to the point at which it has decayed by 50% (T50) provides 
an index of the speed of the processes involved in removing Ca from the cytoplasm and so inducing 
relaxation.  Mean data for T50 is shown in Figure 4-8. Although the trace in Figure 4-6 (A) shows some 
prolongation of T50 in the AC group, there is no statistical significance of the difference in the T50 in 
the sham and the AC groups at 30 days after the operation (T50 = 111 ± 12 ms, n=6, in the sham 
group and 122 ± 8 ms, n=6, in the AC group, Student’s t-test, p=0.459). At 60 days after the 
operation and when heart failure has developed at the 150 day end point, the T50 in the AC group is 
prolonged indicating that the cellular processes involved in removing Ca from the cell have slowed.  
(At 60 days, T50 = 110 ± 4 ms, n=9, in the sham group and 124 ± 4 ms in the AC group, Student’s t-test, 
*p=0.035; at 150 days, T50 = 115 ± 5 ms, n=10, in the sham group and 132 ± 6 ms, n=10, in the AC 
group, Student’s t-test, *p=0.038). 
    Adding the TTP and T50 times together provides an index of the overall function of the Ca release 
and removal processes.  These times are shown in Figure 4-9. The TTP + T50 is not different between 
the sham and the AC groups at 30 and 60 days after operation, (at 30 days the TTP + T50 =, 180 ± 20 
ms, n=6, in the sham group and 193 ± 11 ms, n=6, in the AC group, Student’s t-test, p=0.584; at 60 
days the TTP + T50 =  200 ± 9 ms, n=9, in the sham group and 205 ± 11 ms, n=11, in the AC group, 
Student’s t-test, p=0.763). At the 150 day end point when we suspect heart failure is well developed 
the TTP + T50 is prolonged in the AC group (173 ± 5 ms, n=10, in the sham group and 200 ± 6 ms, 
n=10, in the AC group, Student’s t-test, **p=0.004). 
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Figure 4-4. The typical Ca transient recorded with the concomitant action potential from a GP 
cardiomyocyte at 30 days after the sham operation.  
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(A) (B) 
Figure 4-5. Ca transients measured at 30, 60, and 150 days post-operatively.  
Panel A shows typical traces of Ca transients recorded from cardiomyocytes from sham and AC groups at the 
various post-operative timepoints. Pooled data corresponding to the timepoints are shown in panel B. (n= cell 
numbers isolated from 3-8 animals) 
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Figure 4-6. Ca transient changes during the progression towards heart failure in the sham (A) and 
AC (B) group.  
There is no significant difference in Ca transients among 3 time points in the sham group. Ca 
transients increase at the compensated hypertrophy stage (60 days after the AC operation, Tukey’s 
multiple comparison test, ***p<0.001), and then decrease when end stage heart failure develops at 
the 150 day end point (Tukey’s multiple comparison test, ***p<0.001).  (n= cell numbers isolated 
from 3-8 animals) 
 Electrophysiological Changes During Progression of Hypertrophy toward Heart 
Failure 
 
101 
 
  
Figure 4-7. Time to peak (TTP) amplitude of the Ca transient measured at 30, 60, and 150 
days after the sham and the AC operation.  
(n= cell numbers isolated from 3-8 animals) 
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Figure 4-8. Time from peak to 50% decay (T50) of the Ca transients measured at 30, 60, 
and 150 days after the sham and the AC operation.  
(n= cell numbers isolated from 3-8 animals) 
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Figure 4-9. Time to peak amplitude (TTP) plus time from peak to 50 % decay (T50) of the 
Ca transient measured at 30, 60, and 150 days after the sham and the AC operation.  
(n= cell numbers isolated from 3-8 animals) 
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4.5 Sarcoplasmic reticulum calcium content measurement 
4.5.1 Aim 
    The changes in Ca transient amplitude may be, at least partially, mediated by changes to SR Ca 
content since it is a common finding that the SR Ca uptake process is compromised in heart failure. 
Therefore the aim of the work detailed in this section was to assess if the SR Ca content showed 
progressive changes that paralleled the severity of the decline of whole heart contraction and 
disease state.  
    SR Ca content was measured using rapid applications of caffeine as detailed in Chapter 2.  Caffeine 
increases the open probability of the RyRs and so causes release of Ca from the SR
252
. If caffeine 
application is maintained, Ca cannot be re-sequestered by the SR. SERCA is still active but the SR 
cannot retain the Ca because of the maintained leak of Ca through the RyRs.  Ca is expelled from the 
cell by the Na/Ca exchange which produces an inward Na current
240
. This inward Na/Ca exchange 
current (INCX) has been measured and is used to calculate SR Ca content
234,253
. 
  
4.5.2 Method 
    Cardiac myocytes were placed on a laminin-coated glass coverslip and were superfused with the 
NT solution containing 2 mM Ca. Once steady-state cell contractions were achieved by pacing at 1Hz, 
stimulation was temporarily interrupted. The cell was voltage clamped at -80 mV and the 
superfusate changed rapidly to a NT solution containing 20 mM caffeine. Quantitative 
measurements of SR Ca content were made by recording and integrating the inward (Na/Ca 
exchange) current induced by the rapid application of caffeine. (See Figure 4-10). 
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Figure 4-10. Measurement of SR Ca content by integrating the inward Na/Ca exchange current 
produced by application of 20 mM caffeine.  
20 mM caffeine was rapidly applied (blue bar) to release Ca stored in the SR. The SR Ca content was 
measured by recording and integrating (blue hatched area) the inward current that is produced. The 
calculated ∫INCX represents SR Ca content.  
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4.5.3 Results 
    At the 30 day timepoint the SR load in the AC group is 34% more than the sham group (Figure 4-11 
A, SR Ca content = 19.26 ± 1.39 μM/L, n=19, in the sham group and 25.85 ± 4.28 μM/L, n=12, in the 
AC group, Student’s t-test, *p=0.047) and 103% greater at the 60 days timepoint (Figure 4-11 B, SR 
Ca content = 21.58 ± 3.52 μM/L, n=5, in the sham group and 43.72 ± 5.84 μM/L, n=17, in the AC 
group, Student’s t-test, *p=0.030) than  the respective sham group. After 150 days of AC the SR load 
is significantly less than in the sham group (Figure 4-11 C, SR Ca content = 31.82 ± 3.81 μM/L, n=7, in 
the sham group and 15.22 ± 3.09 μM/L, n=8, in the AC group, Student’s t-test, **p=0.005).  
    The changes of SR load in the sham group show no significant difference (Figure 4-12 A, Tukey’s 
multiple comparison test, p>0.05). In the AC group, during the progression of heart failure (see 
Figure 4-12 B), the SR load increases initially  25.85 ± 4.28 μM/L at 30 days after AC to 43.72 ± 5.84 
μM/L at 60 days after AC (Tukey’s multiple comparison test, *p<0.05). However, later, at 150 days 
when heart failure starts to occur the SR load decreases to 15.22 ± 3.09 μM/L (Tukey’s multiple 
comparison test, **p<0.01). 
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Figure 4-11. Mean measurements of SR Ca content in the sham and the AC groups at 
30, 60, and 150 days after the operation.  
(n= cell numbers isolated from 3-5 animals) 
  H Y Ke                                   Calcium Handling During Progression of Heart Failure 
 
108 
 
 
 
 
 
 
 
Figure 4-12. The changes to SR Ca content during the progression towards heart 
failure in the sham (A) and AC (B) group.  
(n= cell numbers isolated from 3-5 cells) 
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4.6 Discussion 
4.6.1 Prolongation of AP during the progression of hypertrophy toward heart failure 
    The action potential (AP) is the initiating event in E-C coupling, driven by the interaction of many 
ion channels and transporters
11
. The action potential duration (APD) in ventricular myocytes is 
longer than that in atrial myocytes or other conductive cells
11,12
. This longer APD in ventricular 
myocytes probably prevents the formation of aberrant conduction pathways by maintaining a long 
effective refractory period and this helps preserve a period of relaxation for ventricles to reload 
adequately. Therefore its prolongation during the progression towards heart failure may affect 
cellular Ca handling and contraction. Indeed it has been shown that APD is closely linked to SR Ca 
content
172
. 
    The prolongation of APD observed at 30 days after AC might reflect an increase of Ca influx 
required to induce more powerful contraction against the surgically-increased aortic pressure. 
Although the fractional shortening data at 30 days after AC shows a significant decrease compared 
to pre-operation amounts, the contractile function still meets the demand of the circulation. When 
progressing to the probable compensated hypertrophy stage at 60 days after AC, a further 17% 
prolongation in APD compared to that at 30 days post AC is noted. The prolongation of APD remains 
unchanged when the hearts start to fail around 150 days post AC, however, the FS drops significantly 
and signs of circulation insufficiency appear. Alterations to other mechanisms, such as reduced SR 
content and compromised Na/K ATPase and Na/Ca exchange function, which control the calcium 
handling, might lead to this decompensation of contractile function. 
    Although prolongation of APD could be produced by increased Ca influx and lead to larger inward 
depolarizing current, other ionic currents have been observed to change during the progression to 
HF.  The prolongation of APD could be achieved by the overall effects of inward (depolarization) and 
outward (repolarization) currents, the main inward ones being ICa, INa,L, INCX and outward ones being 
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IKr, IK1, Ip. Generally speaking, a decrease in the outward repolarizing current combines with an 
increase in inward depolarizing current to lead to a prolonged AP. The APD prolongation is thought 
to allow more Ca influx thus more SR Ca release to compensate for the increased cardiac stress and 
demand of the circulation. This might explain the APD prolongation noted at 30 days after AC in this 
study. However, when progressing to HF, this mechanism is not effective enough to compensate for 
the decline in cardiac contractility. Alterations of other Ca regulating mechanisms may be 
responsible for the decompensation of heart function.  
    A longer APD will promote slower relaxation, which is important for a better ventricular refilling, 
but the downside is that the prolongation might lead to increased arrhythmogenesis, especially early 
afterdepolarizations (EADs) at low heart rates
11,12
. EADs might induce the subsequent occurrence of 
ventricular tachycardia (VT)
254,255
, that might also explain the sudden death in a small number of our 
GPs 60 to 150 days after AC.      
In one way, these changes to ionic currents transform AP shape and duration; in the other way, 
studies have indicated that modulation of AP could simulate alterations in Ca handling in HF. 
Bouchard et al. reported that modulated AP by a voltage-clamp method could alter the ICa,L thus 
influencing the SR Ca release in rats
256
. Even more, modulating the AP has been proposed to 
enhance EC coupling
167
 and SR load
172
 reversing the decline of contractility caused by alterations in 
Ca handling.  
 
4.6.2 Alterations of calcium handling during progression of hypertrophy toward heart 
failure 
4.6.2.1 Alterations in Ca handling: the early response 
    The action potential activates Ca influx that ultimately causes Ca to be released from the SR via 
RyRs. The size of the Ca transients is dependent on the efficacy of the EC coupling process and the 
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amount of Ca in the SR. In this study, Ca transients were not altered at 30 days after the AC 
operation then increased at 60 days post- operatively. However, the SR Ca content increased more 
quickly because it was increased 30 days after the AC operation. In the compensated hypertrophy 
stage perhaps around 60 days after the AC operation, the SR Ca content remained increased and an 
increase of Ca transients was also noted.  This might occur by more Ca being released from a better 
loaded SR.  
    The SR is the main intracellular reservoir that stores Ca. In a normal cardiac cycle, the Ca released 
from the SR during the process of CICR should be pumped back to the store by SERCA to maintain a 
stable amount of releasable Ca for the next cycle. The increase in SR Ca content could be an early 
response to AC in an attempt to increase more releasable Ca that may increase the force of 
contraction. It could be seen as a compensatory mechanism that works against the increased 
afterload created by the surgical constriction of the aorta. This early response could be mediated by 
the activation of the Ca/calmodulin-dependent protein kinase II (CaMKII). When a mechanical stress 
was induced by the increased afterload, stimulation of the adrenergic signalling pathway might 
activate the kinase through a G-coupled protein receptor (GCPRs) pathway
127,144
. The activation of 
the CaMKII would increase the ICa via phosphorylation of Ca channels and enhance the SERCA 
function through phosphorylation of PLB thus increasing the SR Ca content.  Increasing Ca current 
can prolong the APD
124,126
  which was observed even at the 30 day timepoint. Increased 
phosphorylation will also increase the open probability of the RyRs but this would be detrimental 
rather than beneficial because this has been shown to increase SR Ca leak, lower SR Ca content and 
be potentially arrhythmogenic.  
    The open probability of the voltage-gated LTCC is increased via phosphorylation at a threonine site 
(Thr498) on the β subunit by the CaMKII
26,122,124
 which produces the ICa,L facilitation. The ICa,L can also 
be increased by PKA phosphorylation of the channel at the α1 subunit, following its activation by Gs-
protein
11,12,26,27
.  
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    The SERCA function is regulated by the PLB, which inhibits SERCA when not phosphorylated
59,60,66
. 
The activated CaMKII increases the phosphorylation of PLB thus enhancing the SERCA function to 
reuptake more Ca and increasing the SR Ca content.   
SR Ca release is induced by Ca binding to RyRs.  Reasonably, an increase of Ca influx could induce 
more Ca to be released from the SR via RyRs. Marks and other researchers
53,55,56,174
 proposed that 
the β-adrenergic stimulation not only augments Ca influx, but also causes hyperphosphorylation of 
RyRs through PKA, which increases the dissociation of the regulatory protein FKBP12.6 and increases 
the open probability of RyRs inducing more SR Ca release. In this study, the increase in Ca transients 
corresponded to elevation of SR Ca content and prolongation of APD, in which the prolongation of 
APD may be due to increased opening of the voltage-gated LTCC. An increase in the reverse mode 
INCX that may be related to an alteration in Na/K ATPase function might also partially contribute to 
the increase of Ca transient amplitude. Besides the increase in the amplitude of Ca transients, a 
prolongation of the time from peak to the 50% amplitude (T50) was also noted in this compensated 
hypertrophy status, although the TTP + T50 remained unaltered. The prolonged decay indicated the 
longer time spent in Ca removal from the cytoplasm, which might be the result of increased SR Ca 
release or compromised efflux and/or uptake mechanisms. The net effect of all these actions is to 
augment the cardiac contractility to overcome the increased pathological afterload.  
 
4.6.2.2 Alterations of Ca handling in heart failure 
    While decompensation and heart failure happen at 150 days after the AC operation, a significant 
decrease of Ca transient amplitude occurred accompanied by prolonged TTP, T50 and TTP + T50. The 
decrease in Ca transient amplitude corresponded to the depletion of SR content that presumably 
causes decreased SR Ca release. Depletion of SR Ca content can be attributed to alterations in SERCA 
reuptake and perhaps NCX extrusion. Since de la Bastie
192
 first reported this finding in a rat HF model 
produced by pressure-overload, down-regulation of SERCA has been  reported in many human and 
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animal models of HF
148,160,194,195,197,199
. del Monte et al.
257
 first tried to enhance SERCA function by 
overexpressing the protein using adenovirus with positive results. Further studies have 
demonstrated equally promising results with this novel therapeutic approach
150,204,258
.  Hajjar and 
colleagues introduced the gene therapy using modified adeno-associated vector (AAV) to deliver 
SERCA gene via percutaneous coronary infusion and have had encouraging results in terms of 
efficacy and safety from the phase I and II human clinical trials of the Calcium Upregulation by 
Percutaneous Administration of Gene Therapy in Cardiac disease (CUPID)
202,203
. A phase IIb CUPID 
trial is ongoing and including a larger patient population
206
.    
    Along with the decline of SERCA function in HF, its regulatory protein PLB was also found down-
regulated
59
. This nearly proportional decrease in PLB might be a compensatory mechanism 
responding to SERCA dysfunction to prevent massive suppressive effect. However, reduced 
phosphorylation of PLB was also reported in HF
59,60,66,149,196
, which would further inhibit the SERCA to 
uptake Ca.  
Nevertheless, the long-term, chronic activation of the CaMKII hyper-phosphorylated the RyRs, 
which not only increases their open probability but also induces dissociation of FKBP12.6 from RyRs, 
causing Ca depletion of the SR. This leaky mechanism of FKBP12.6 dissociation in HF is seen to 
contribute to the decreased SR Ca content and prolongation of relaxation. These effects could 
explain the finding of prolongation of T50 and TTP + T50 in this study. Moreover, the spontaneous SR 
leak can cause an increase in the depolarizing INCX, which can be arrhythmogenic and cause delayed 
afterdepolarizations and atrial fibrillation
125,259,260
.     
    Decreased SERCA reuptake of Ca back to SR shifts the proportion of Ca being extruded from the 
cell by NCX, and this further depletes the SR Ca storage. In the normal physiological condition, 70% 
and 25-30 % of intracellular Ca is removed by SERCA and NCX respectively
11,12
. Therefore when 
SERCA function declines, more Ca tends to be extruded by NCX. Although the increased NCX 
extrusion improves the diastolic relaxation, however, this also depletes the SR Ca content. The NCX 
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function is determined by membrane potential, intracellular [Ca] and [Na]. Therefore, the Na/K 
ATPase, which is mainly responsible for the intracellular [Na] regulation, also plays an important role 
in intervening Ca handling via NCX and this will be examined in the next Chapter.  
    Besides, the reduced amplitude of Ca transients and delayed time-to-peak were also noted in this 
study when heart failure developed, which represented an inefficient Ca release and thus a weaker 
contraction. A lack of releasable Ca could lead to this slow release, however, dyssynchrony of LTCC 
and clusters of RyRs might play an equally important role. Evidence has shown that the CICR is 
conducted delicately within a microdomain- the couplon, which consists of a close approximity of 
LTCC and its corresponding cluster of RyRs
10,43,46,48,216,222
. Despa and Bers introduced novel cleft-
targeted Ca sensors allowing direct measurement of Ca concentration changes in this Ca 
microdomain ([Ca]Cleft)
261
. They fused Ca sensors with varying affinities, (GCaMP2.2 – high Ca affinity 
and GCaMPs.sLow – low Ca affinity) to FKBP12.6, which binds to RyRs selectively. The Ca sensors 
with different affinities allowed the measurement of the [Ca] in the cleft environment during CICR 
and at diastole. Such measurements showed a gradient of [Ca] from cleft to bulk cytoplasm. A 
structural-functional alteration in this Ca microdomain causing dyssynchronous Ca release has also 
been reported in HF, which is related to the changes to the t-tubule 
organization
41,43,49,214,215,218,221,222,262,263
.  
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5 NA/K ATPASE CURRENT CHANGES IN HYPERTROPHY AND HEART 
FAILURE 
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5.1 Introduction 
The ionic gradients upon which the membrane potential depends are maintained by Na/K ATPase 
(NKA) also called the Na-K pump, which extrudes 3 Na ions from the cytoplasm whilst pumping 2 K 
ions into the cell
12,81
.  This activity consumes energy from hydrolysis of ATP to against the Na and K 
concentration gradients and produces a pump current (Ip). In the heart the pump function is 
important because it maintains the intracellular Na concentration, which subsequently influences 
the function of Na/Ca exchange (NCX) therefore regulating the Ca handling.  It remains largely 
unknown how the Na/K pump functions during the onset of hypertrophy and the progression 
towards heart failure.  The aim of the work detailed in this chapter is to characterize the function of 
the pump in these circumstances.  
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5.2 Method 
    The methods used in these experiments are described in detail in Chapter 2.  
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Figure 5-1. Na/K ATPase current in guinea pig cardiomyocytes.  
Panel A shows a recording of the inward current that appears following exposure of a cell isolated from 
the heart of a 150 day sham animal to 5 μM dihydro-ouabain (DHO).  The high affinity component of the 
Na/K ATPase (α2 isoform) is inhibited (doubleheaded arrow). 500 μM strophanthidin is applied later to 
produce complete inhibition of the current (see second doubleheaded arrow).  Panel B shows the same 
type of experiment carried out on a cell isolated from the heart of a 150 day AC animal. 
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5.3 Results 
    Figure 5-1 shows the experimental procedure used to identify the Na/K ATPase current. The 
recordings were made in voltage-clamped cells held at -80mV with a zero-Ca, zero-K superfusate 
containing 2 mM Ba and 5 mM Ni.  Ba was used to block K channels and Ni was used to block Ca 
channels and NCX and the zero K and Ca solution prevented inward leak K and Ca currents. Panel A 
shows a typical recording of the inward current that appears following exposure of a cell isolated 
from the heart of a 150 day sham animal to 5 μM dihydro-ouabain (DHO).  This inhibits the high 
affinity component of the Na/K ATPase (α2 isoform) producing an inward current of a size indicated 
by the doubleheaded arrow.   The current is inward because DHO is inhibiting the outward current 
normally produced by the Na/K ATPase.  Then 500 μM strophanthidin is applied to produce 
complete inhibition of the current (see second doubleheaded arrow).   
    The mean Na/K ATPase current changes between sham and AC groups are shown in Figure 5-2 and 
the changes of pump current in the sham and AC groups during the progression of heart failure are 
displayed in Figure 5-3. No significant difference between sham and AC groups was noted at 30 days 
after the AC operation (1.0 ± 0.10 pA/pF, n=17, in the sham group and 1.1 ± 0.11 pA/pF, n=11 in the 
AC group, Student’s t test, p=0.698). From 60 days after the AC operation, the pump current 
decreases significantly (Tukey’s multiple comparison test, ***p<0.001) in the AC group to 0.54 ± 0.10 
pA/pF, which is also significantly different from the current in the sham group (1.10 ± 0.16 pA/pF, 
n=15, Student’s t test**p=0.007).  At 150 days after the operation, the reduction in Na/K ATPase 
current in the AC group is maintained (0.86 ± 0.13 pA/pF, n=25, in the sham group and 0.51 ± 0.06 
pA/pF, n=15, in the AC group, Student’s t test, *p=0.043), and is not different from the current at 60 
days post AC (Tukey’s multiple comparison test, p=0.784).  There is no significant difference noted in 
the sham group during the progression (Figure 5-3 A, one-way ANOVA, p>0.05). 
    Figure 5-4 displays mean Na/K ATPase current components blocked by dihydro-ouabain (DHO) and 
strophanthidin, together with the total pump current measured at 30, 60, and 150 days post 
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operatively. In both sham and AC group at every stage, the α2-derived current was always smaller 
than that produced by the α1 isoform. Figure 5-5 shows the ratio of DHO-blocked current / total 
pump current measured at different stages in both sham and AC groups. The ratios (around 45%) are 
not different between any group at any stage (Two-way ANOVA, p>0.05 in all groups tested). 
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Figure 5-2. Na/K ATPase current at 30, 60, and 150 days post operatively.  
Panel A: Pump current shows no difference between sham and AC groups at 30 days after the 
operation. Panel B: At 60 days after the operation, the stage of compensated hypertrophy, the 
pump current is significantly smaller in the AC group. Panel C: At 150 days after the operation, 
when heart failure occurs, the pump current keeps significantly smaller in the AC group.  (n= 
cell numbers isolated from 3-5 animals) 
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Figure 5-3. Na/K ATPase current changes during the progression of heart failure in the sham (A) 
and AC (B) groups.  
There is no significant difference in the sham group (A). At 60 days after operation when 
compensated hypertrophy occurs, the pump current starts to decrease and this situation is 
maintained in end stage heart failure (B).  (n= cell numbers isolated from 3-5 animals) 
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Figure 5-4. The relative amounts of Na/K ATPase current that can be attributed to the α2 (blocked by 
dihydro-ouabain (DHO)) and α1 isoforms (Blocked by strophanthidin) and the total pump current at 
30, 60, and 150 days post operatively.  
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Figure 5-5. Ratios of α2 to total Na/K ATPase current at 30, 60, and 150 days after the AC 
operation.  
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5.4 Discussion 
    The function of the Na/K ATPase is to maintain the chemical gradients for Na and K that exist 
across the cell membrane upon which the membrane potential depends. This pump uses energy 
from the hydrolysis of ATP to pump 3 Na ions out of the cell and 2 K ions in to the cell. The pump 
therefore creates an outward current (Ip) and is electrogenic. When inhibited, the outward current is 
lost and the current is recorded as inward.   
    An increase of Intracellular [Na] has been reported in guinea-pig
108-110
, rabbit models
111,112
, and in 
human heart failure
113
. Since the Na/K ATPase regulates the intracellular Na concentration ([Na]i), it 
influences the function of Na/Ca exchange (NCX), which regulates the Ca handling not only at the 
dyad and during CICR, but also during relaxation and the diastolic period. Several reports have 
shown reduced Na/K ATPase activity in heart failure with elevated [Na]i, which is expected to be 
inotropic
11,115,117,264
. This elevated [Na]i would cause a decrease in the amount of Ca expelled through 
NCX during the cardiac cycle, and the reverse mode NCX would bring more Ca into the cell producing 
a similar inotropic effect as cardiac glycoside therapy
12
. In this study, the pump function declines at 
60 days after AC when compensated hypertrophy has developed and then remains low throughout 
the progression of the disease. This change in pump function might trigger an inotropic response 
that compensates and prevents an early decline in muscle function by helping to load the SR which 
maintains the Ca transient amplitude (Figure 5-6).     
    Isoforms of α subunits of the pump in the heart appear to be expressed differently in different 
species
265
. In human heart, α1, α2, and α3 are present
266,267
, whereas in guinea-pig, rat, and mouse 
hearts only α1 and α2 isoforms are present
104,241
. The expression of these three isoforms in human 
heart has been  reported to be relatively equal
267
 to a ratio of 62% α1, 23% α2, and 15% α3
107
.   
    Berry et al.
265
 and James et al.
104
 have shown that mouse Na/K ATPase α1 and α2 isoforms are 
localized differently in t-tubules and surface sarcolemma, and act in different roles in regulating E-C 
coupling. The α1 isoform appears to influence bulk cytoplasmic [Na] while the α2 isoform may 
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regulate [Ca]i particularly in the dyadic space by closely regulating NCX positioned predominantly in 
t-tubules
104
. The protein expression and function of the Na/K ATPase both declined in human failing 
myocardium
115
.  This group found that the expression of α1, α3, and β1 subunits of the Na/K ATPase 
all decreased. However, Allen and colleagues
268
 reported that there were no changes to the amount 
of mRNA coding for the α1, α2, and α3 subunits in failing human cardiomyocytes. According to 
Verdonck and colleagues’ review
269
, most rat HF models show a decrease in the α2 isoform, an 
increase in the α3 isoform, but no change in the α1isoform at protein and mRNA levels. 
    However, the changes in expression are not necessary compatible with functional alterations. 
Bossuyt et al.92 found all 3 α isoforms decreased in protein expression but the Na/K ATPase 
function was not changed in a pressure and volume overload induced HF model in rabbit. Despa 
and co-workers111 reported a similar finding of unchanged Na/K ATPase function although 
increased [Na]i in a rabbit TAC HF model. Verdonck et al.114 also reported a similar finding in A-
V blocking-induced hypertrophy in the dog.  
    However, Swift and colleagues120 showed a declined Na/K ATPase function, which is due to 
decreased expression of the α2 isoform, in a rat MI model. Louch et al.270 supported such 
findings in a SERCA knockout mice model and proposed that the decrease in the α2 isoform 
would cause an increase in [Na]i thus decreasing Ca extrusion via NCX. Therefore the changes in 
Na/K ATPase expression and function in HF may be dependent on species and heart failure 
etiology.  The possible role played by PLM in determining Na/K ATPase function is poorly 
understood92, but it may be involved in the overall response to TAC. 
    In this study, the total pump current declines from about 60 days and the relative contributions 
from α1 and α2 isoforms do not appear to change.  The ratio of the α2 isoform-responsible (DHO-
inhibited) pump current to total pump current is constantly around 45% in this study in both the 
sham and AC groups at all stages. This implies that there is a global reduction in pump activity with 
both isoforms affected to similar extents. However, the relationship between this decline in pump 
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activity and the global [Na] causing alteration in cardiac function, and also the respective roles of 
different α isoforms, needs to be further studied.    
    Studies have suggested that the α2 isoform play a preferential role in regulating Ca handling in 
cardiomyocytes with the coupling with NCX
79,80,86,98,102,103,120,121,271
, although some argue that the α1 
isoform also regulates cardiac contractility
106,272
. It has been known that the α2 isoform has a higher 
affinity to ouabain than the α1 isoform, which is the working mechanism of digitalis 
inotropy
11,12,42,79,271
. The Bers’ group investigated the role of the α2 isoform in regulating Ca handling 
using SWAP mice in which the α1 and α2 isoforms had reverse affinities for ouabain
121
 and rats 
overexpressing  α1 and α2 isoforms
271
. The SWAP mice were produced by mating mice that have 
ouabain-sensitive α1 isoforms (α1
SS
 α2
SS
) with mice that have ouabain-resistant α2 isoforms (α1
RR
 
α2
RR
)
106,121
.  The change in affinity for ouabain does not alter the enzymatic properties of the ATPase 
or the sarcolemmal distribution of isoforms. They reported that the α2 isoform preferentially 
regulated SR Ca release, and its overexpression reduced the severity of hypertrophy caused by 
pressure-overload. However, Rindler et al.
122
 used a cardiac specific knockout of the α2 isoform in 
mice and reported that its absence prevented the development of hypertrophy in a pressure-
overload model  but had little influence on the basal cardiac phenotype.  
    Ventricular myocytes isolated from failing hearts have been shown by a number of 
groups
41,43,46,49,214,215,218,219,221,222,263
 to have altered t-tubule organization.  The shrinking or 
disappearance of t-tubules as HF progresses causes RyR clusters to separate from T-tubules with 
larger gaps than normal or "orphaning" of RyR clusters where there are no t-tubules nearby. These 
uncoupled RyR clusters cannot be as well controlled by CICR.  As a result they may activate 
spontaneously and could potentially be arrhythmogenic.  If the α2 isoform is preferentially located in 
t-tubules then it would be reasonable to conclude that α2 pump current would be affect more than 
α1.  However, this does not appear to be the case suggesting perhaps that there is a reorganization 
of isoform location. 
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Figure 5-6. The mean measurements of (A) Ca transients, (B) SR Ca content, and (C) total Na/K ATPase 
current at 30, 60, and 150 days after aortic constriction.  
Ca transients and SR Ca content appear to  increase (indicated by red lines) in function when compensated 
hypertrophy develops, while Na/K ATPase pump function declines (indicated by blue lines) at this stage. As 
heart failure occurs the Ca transients, SR Ca content, and Na/K ATPase pump function all show declines.  
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6 NA/K ATPASE ΑLPHA ISOFORMS DISTRIBUTIONAL CHANGES IN A 
GUINEA PIG MODEL OF HEART FAILURE  
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6.1 Introduction 
    In Chapter 5 it was shown that the Na/K ATPase current was reduced in heart failure with a similar 
reduction in both isoforms expressed. Some reports indicating that the α2 isoform may play an more 
important role in regulating Ca handling
104
 compared with the α1 isoform and that it may be 
distributed preferentially in the t-tubules
273
.  Others show the α1 isoform may be important in 
regulating bulk cytoplasmic [Na]i
104
 and may be localized predominantly at the surface 
sarcolemma
273
 .  The aim of this part of the study was to investigate the distribution of α1 and α2 
isoforms in the sarcolemma in a guinea pig HF model created by aortic constriction to see if there is 
a change in isoform distribution in heart failure.   
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6.2 Method 
    These have already been described in detail in Chapter 2. 
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Figure 6-1. Immunocytochemical staining and confocal imaging of Na/K ATPase α1 and α2 
isoforms.  
(A) Zeiss LSM780 confocal microscope (Carl Zeiss Microscopy GmbH) with Argon laser was used for 
imaging. (B) Isolated cardiac myocytes were adhered and immunocytochemically stained on 35 mm 
petri dishes with a 14 mm microwell and No. 0 coverglass (MatTek). (C) Confocal images of Na/K 
ATPase α1 and α2 isoforms from cardiac myocytes isolated from guinea-pigs at 150 days after the 
sham and aortic constriction operations (scale bar = 10μm).  
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6.3 Result 
6.3.1 Distribution and localization of the Na/K ATPase α1 isoform 
    The immunofluorescence intensity of the α1 isoform measured by an area-fixed region of interest 
(ROI) shows a lower value in the AC group compared with the sham group (see Figure 6-2 A, 35.83 ± 
2.67 a.u., n=18, in the sham group and 14.98 ± 3.17 a.u., n=18, Student’s t-test, ***p<0.001). The 
linear measurements of the α1 isoform immunofluorescence intensity using a length-fixed ROI show 
regular patterns of staining in both the sham and AC groups (Figure 6-2 B). The immunofluorescence 
intensities at each peak are not significantly different between the 2 groups. The spatial frequency 
analysis of the α1 isoform distribution (Figure 6-2 C) shows very comparable curves for the sham and 
AC groups, where each group has one single prominent spike. This means that there is no difference 
between the distribution intervals of both groups. The calculated interval of the α1 isoform 
distribution is 1.8 μm (Student’s t-test, p=0.980). 
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Figure 6-2. Immunocytochemical staining of Na/K ATPase α1 isoforms in the sham and AC groups 150 
days after the operation.   
Panel A: Immunofluorescence intensity measured by a fixed ROI has a lower value in the AC group. Panel 
B indicates the linear measurement of immunofluorescence intensity, which shows regular patterns in 
both groups and no significant difference of immunofluorescence intensities at each peak. In panel C, 
the spatial frequency analysis performed by the MatLab® software shows nearly compatible curves with 
one single prominent peak of both groups, which means the intervals of distribution are the same in 
both groups, which is calculated as 1.8 μm. (n= cell numbers isolated from 3-4 animals) 
 Na/K ATPase Alpha Isoforms Distributional Changes in A Guinea Pig Model of Heart 
Failure 
 
135 
 
6.3.2 Distribution and localization of the Na/K ATPase α2 isoform 
    The immunofluorescence intensity of the α2 isoform measured by an area-fixed ROI also has a 
lower value in the AC group (see Figure 6-3 A, 24.62 ± 1.44 a.u., n=46, in the sham group and 18.65 ± 
2.76 a.u., n=25, in the AC group, Student’s t-test, *p=0.038). The linear measurements of the 
immunofluorescence intensity of the α2 isoform also show regular patterns in both the sham and AC 
groups, although the intervals are not the same (Figure 6-3 B). Furthermore, the 
immunofluorescence intensities at each peak are higher in the AC group than that in the sham group 
with a statistical significance, which indicates the enhanced expression of the α2 isoforms at these 
localizations. The result of the spatial frequency analysis for the α2 isoform distribution is different 
between the sham and AC groups, although there is no statistical significance (Student’s t-test, 
p=0.233). Each group still has one single prominent spike, which suggests that the distribution of the 
α2 isoforms in each group is regular (Figure 6-3 C). The calculated intervals of distribution are 2.25 
μm in the sham group and 1.8 μm in the AC group. 
 
  
  H Y Ke                                   Calcium Handling During Progression of Heart Failure 
 
136 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-3. Immunocytochemical staining of the Na/K ATPase α2 isoform in the sham and AC groups 
at 150 days after operation.   
Immunofluorescence intensity measured by a fixed range of interest (ROI) shows a lower value in the 
AC group (panel A).Panel B indicates the linear measurement of immunofluorescence intensity and 
shows regular patterns in each group, however, immunofluorescence intensities at each peak are 
significantly higher in the AC group. In panel C, the spatial frequency analysis performed by the 
MatLab® software shows one single prominent peak in each group but the regularities are different 
from each other. The regular intervals are calculated as 2.25 μm in the sham group and 1.8 μm in the 
AC group. (n= cell numbers isolated from 3-4 animals) 
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6.4 Discussion 
    This study used an immunocytochemical staining method to investigate changes of α1 and α2 
isoforms in isolated ventricular cardiomyocytes in HF. Currently no commercial NKA isoforms 
antibodies are produced specifically for GP tissue. Rabbit is a quite different species of animal to GP, 
so its antibodies for NKA α1 and α2 isoforms are better suited due to less cross-reactivity occurring 
from endogenous immunoglobulins of cells.  The affinity and selectivity of these antibodies on GP 
cells could be determined by gel electrophoresis and Western blotting. 
The immunocytochemical fluorescence densities of the α1 and α2 isoforms both decrease in HF, 
which is compatible with the functional findings of the declined pump current described in section 
5.3. Regarding the distribution of the α1 and α2 isoforms in the sarcolemma, the results show no 
difference of α1 isoform arrangement between the sham and AC groups, which means that although 
the density of the α1 isoform decreases, the arrangement of isoform is still regular with the same 
intervals. However, the α2 isoforms distributed regularly but with different intervals in the sham and 
AC groups. The interval between the α2 isoforms in the AC group is 1.8 μm, which is shorter than the 
interval of 2.25 μm in the sham group, although there is no statistically significant difference.  This 
finding reveals that the α2 isoforms may not only change in expression, but also alter in their 
localization, while the α1 isoforms only change in expression.  
    It has been proposed that the α1 isoforms are responsible for bulk [Na] control and distribute 
evenly in the sarcolemma, while the α2 isoforms are more concentrated in the t-tubules and 
colocalize with NCX closely linking to Ca handling
42,104,121,271
. Although the overall density of the α2 
isoforms decreases in HF, the expression of the α2 isoforms at their preferential location, which 
might be t-tubules, was enhanced. Therefore the change to the α2 isoform localization might 
underlie the poor Ca handling in HF, and the localization change might be caused by the remodelling 
of t-tubules.  Silvermann et al.
273
 reported similar findings of Na/K ATPase α isoforms distribution in 
guinea pig ventricular myocytes in that the α2 isoform localized predominantly in the t-tubule while 
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the α1 isoform localized mainly in external sarcolemma. Despa and co-workers
121
 indicated that in 
mice cardiomyocytes, the α2 isoform distributed mainly in the t-tubule, whereas the α1 isoform 
localized in both the t-tubule and the external sarcolemma. However, McDonough and colleagues
274
 
made the reverse observation in adult rat ventricular myocytes showing that the α1 isoform 
localized preferentially in the t-tubules while the α2 isoform distributed evenly in both external 
sarcolemma and t-tubule. 
    Although the data obtained from immunocytochemical staining shows changes to isoform 
distribution when heart failure occurs, we have less evidence for differential effects on isoform 
abundance. Further investigation about isoforms expression is needed. 
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7 T-TUBULE REMODELLING DURING PROGRESSION OF HYPERTROPHY 
TOWARD HEART FAILURE 
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7.1 Introduction 
    The previous chapter indicated a possible positional re-arrangement of isoforms of the Na/K 
ATPase within the t-tubules. The aim of the work in this chapter was to assess if there were changes 
to t-tubule structure in cells isolated from the hearts of our guinea pig aortic constriction HF model. 
We used wheat germ agglutinin (WGA), which binds to N-acetyl-D-glucosamine and sialic acid 
residues located on the surface of cell membrane, to indicate t-tubules in cardiomyocytes isolated 
from sham- and AC-operated guinea pigs 150 days after the TAC operation. 
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7.2 Method 
    The methods used have been described in detail in Chapter 2. Wheat germ agglutinin (WGA) has 
been used extensively to stain surface membranes, including t-tubules in cardiac myocytes
248,275
. In 
this study Alexa Fluo® 594 conjugated WGA was used to stain the sarcolemma and be a t-tubule 
indicator on isolated ventricular myocytes.  
    Enzymatic isolation of cardiac myocytes was performed as the protocol described before. 
Myocytes were adhered on the glass bottom culture dish by laminin. Then washing quickly with 
phosphate buffer saline (PBS) was carried out for 3 times followed by fixing with 4% 
paraformaldehyde (PFA) for 10 minutes. Finally myocytes were incubated with WGA for 1 hour. The 
above procedures were carried out at room temperature. In some experiments, WGA staining was 
performed concomitantly with Immunocytochemical staining of Na/K ATPase α1 and α2 isoforms. 
Therefore in these experiments, WGA was added one step before the adding of the primary 
antibody. 
    Confocal images were obtained with the same set-up as described in the Immunocytochemical 
staining. The example of acquired images and measurements were shown in Figure 7-1. Average 
fluorescence density was measured using the software ImageJ (NIH, USA) with longitudinal linear 
measurements indicating distribution of t-tubules (Figure 7-1 A) and a fixed range of interest (ROI) 
providing an index of t-tubule density (Figure 7-1 B). Spatial frequency analysis of t-tubules 
arrangement was performed with MatLab® software (The MathWorks® Inc.).  
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Figure 7-1. Membrane staining of sarcolemma with WGA as a t-tubules indicator.  
Isolated cardiomyocytes were stained with Alexa Fluo® 594 conjugated WGA, which shows 
red colour under confocal microscope with excitation by Argon laser. Grossly, the staining in 
the sham group is more homogeneous, whereas we can see some local areas with patchy t-
tubules loss in the AC group (Scale bar = 10μm). Panel (A) shows linear measurements 
indicating the regularity of the t-tubules distribution. Panel (B) indicates an area-fixed region 
of Interest (ROI) was used to measure the fluorescence density, which represents the t-
tubules density.  
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7.3 Results 
    Membrane staining with WGA indicated the distribution and arrangement of the t-tubules as can 
be seen in Figure 7-1. Grossly, the staining is more homogeneous in the sham group; whereas areas 
of patchy t-tubule staining occur in the AC group indicting a loss of t-tubules. The density of 
fluorescence measured with an area-fixed range of interest (ROI) also confirms this gross finding.  
The fluorescence signal intensity is significantly lower in the AC group (Figure 7-2, 14.28 ± 1.01 a.u., 
n=41, in the sham group and 8.33 ± 0.73 a.u., n=20, in the AC group, Student’s t-test, ***p<0.001).  
Figure 7-3 shows the distribution and regularity of the t-tubules measured by a linear ROI. The 
fluorescence signals in the sham and AC groups both show a regular pattern of distribution, although 
the interval in the AC group is shorter than that in the sham group. The spatial frequency analysis 
(Figure 7-4) shows that the t-tubules distribute regularly in the sham and AC groups with intervals of 
2.25μm and 1.8μm respectively, although there is no statistical significance (Student’s t-test, 
p=0.786).   
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Figure 7-2. Average WGA fluorescence density in cells sampled from the AC and sham groups 150 
days after the operation.  
WGA fluorescence density was measured with an area-fixed region of interest (ROI) by ImageJ 
software (NHI, USA) (as shown in Figure 7-1 B). When heart fails, the fluorescence density in the AC 
group is significantly lower than that in the sham group.  (n= cells isolated from 3-4 animals) 
 
 T-tubule Remodelling during Progression of Hypertrophy toward Heart Failure 
 
145 
 
 
 
 
 
 
 
 
Figure 7-3. Linear measurement of WGA fluorescence 150 days after the operation.  
Measurements of WGA fluorescence with a length-fixed linear ROI (as shown in Figure 7-1 A) 
indicate the regularity of the t-tubule organization. These data show regular patterns of fluorescence 
distribution in both the sham and AC groups, although the intervals in the AC group are shorter than 
that in the sham group. 
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Figure 7-4. Spatial frequency analysis of WGA fluorescence intensity 150 days after the operation. 
Spatial frequency analysis of WGA fluorescence intensity representing t-tubule staining regularity 
was performed by MatLab software®. These data show a single prominent high power at one 
spatial frequency in each group. The representing regular intervals of t-tubules are 2.25μm in the 
sham group and 1.8μm in the AC group respectively. 
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7.4 Discussion 
7.4.1 T-tubule remodelling in heart failure 
    The specific invaginating structure of t-tubules in conjunction with those colocalized proteins that 
are responsible for E-C coupling and CICR make t-tubules important in maintaining normal cardiac 
contractile function.  Structural and functional alterations of t-tubules have a closely relation to 
contractile dysfunction in both human and animal models of HF
10,41,43,46,49,214,215,217-222,263
. Wei et al.
221
 
used a method of in situ t-tubule imaging in Langendorff-perfused hearts to investigate the t-tubules 
remodelling during the transition from hypertrophy to heart failure in aortic-banded rats. They 
found that t-tubule remodelling happened before the functional change to the heart. Orchard et 
al.
220
 used the method of detubulation to investigate the relationship between t-tubule dysfunction 
and heart failure or arrhythmogenesis. They found that although dysregulation of t-tubules has been 
found in HF, the net effect of changes to its structure is still unknown. Studies have shown that LTCC, 
NCX, sarcolemmal Ca ATPase, and Na/K ATPase α2 isoform localize preferentially in the t-
tubules
10,40,45,75,262,263,276
.   The LTCC is important for triggering EC coupling and NCX and the 
sarcolemmal Ca ATPase are responsible for Ca extrusion during relaxation.  The Na/K ATPase α2 
isoform regulates [Ca]i via functionally coupling with NCX. Loss of t-tubules occurs in HF and the 
obvious result is changes to the efficiency of the above proteins in maintaining ion homeostasis. Loss 
of t-tubules also affects the synchronous Ca release from RyRs in the dyad and, in turn, this slows the 
TTP of the Ca transient. Decreased Na/K ATPase α2 function in the t-tubule may increase [Na]i 
causing enhanced reverse mode NCX to influx Ca and increase [Ca]i. Altered NCX and Ca ATPase 
function in t-tubule decrease Ca extrusion thus delaying relaxation. Those alterations may be 
responsible for the dysfunction in contraction and relaxation in HF.   
    In this study, we used a method of membrane staining with WGA on isolated ventricular myocytes 
to investigate the changes to density and regularity of the t-tubules in an aortic constriction guinea 
pig HF model. Results of this study show the density of t-tubules significantly decreases in the AC 
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group when heart failure developed. The same finding were also reported in dog rapid-pacing
263
, rat 
hypertensive
277
, mouse MI
218
, pig MI
223
, and sheep rapid-pacing
278
 HF models. Lyon and colleagues 
reported t-tubules loss in human HF of various etiologies
219
. Swift
120
 and Wei
221
 reported the regular 
intervals of t-tubules organization as 1.8 μm and 2 μm in rats, and they were not altered in HF. 
However, in this study, the arrangement of t-tubules remained in a regular pattern, and the intervals 
between them reduced but there is no statistical difference in this change. The regular interval of t-
tubules distribution in the AC group was 1.8 μm, which was narrower than 2.25 μm in the sham 
group. The lack of significant difference might be caused by the fixation procedure or an inadequate 
number of samples.  
    The structural changes to t-tubules further lead to a functional alteration in cardiac Ca handling 
because it causes a dyssynchrony in CICR. A  concept of local Ca control within a microdomain was 
proposed by Stern and colleagues
44
. The close proximity of the t-tubule and junctional SR (jSR) 
makes up a dyadic space, fundamental functional unit of CICR called the couplon. The couplon 
consists of LTCCs and the corresponding clusters of RyRs. This close juxtaposition makes Ca influx via 
LTCC to bind the cluster of RyRs releasing Ca from SR efficient. The observation of Ca sparks arising 
from this dyadic space supports this concept
8
. Many studies
10,46,48,216,222,223,277,279
 have assessed 
spontaneous Ca spark characteristics in relation to t-tubule structure. Song et al.
277
 provided the first 
evidence suggesting the possibility that subcellular heterogeneity of t-tubules might result in 
differences in spontaneous SR Ca release in their publications and they identified “orphaned RyRs” 
which were not in the vicinity of t-tubules and therefore not likely to be under the control of  
dihydropyridine receptors in HF models. Disorganization of t-tubules in HF would cause more 
orphaned RyRs resulting in inefficient EC coupling and dyssynchronous SR Ca release
41,221,223,277
. 
Louch and colleagues
222
 investigated the influence of t-tubule loss on SR Ca release in isolated and 
cultured pig’s and isolated failing human ventricular myocytes. They reported that loss of t-tubules 
fluorescence density was seen in pig’s cardiomyocytes, in those regions dyssynchronous Ca release 
was also found on the confocal scanning line. These findings were also shown in human failing 
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cardiomyocytes, although the dyssynchrony of Ca release was milder than that in pig 
cardiomyocytes. Biesmans and co-workers
280
 studied the relationship of RyR properties and t-tubule 
density in healthy and MI pig ventricular myocytes. They found that diastolic Ca sparks showed 
marked heterogeneity in duration if they did not appear near a t-tubule. Inhibition of NCX but not 
LTCC increased the density and duration of Ca sparks near t-tubules and this increased SR Ca content 
and the number of Ca waves occurring in MI cardiomyocytes.   
    Cells isolated from the present guinea pig HF model show a loss of t-tubule density and a more 
compact arrangement among those remaining t-tubules. The narrower intervals between preserved 
t-tubules might represent a compensatory response to the contractile dysfunction, with which the 
CICR could be possibly conducted more efficiently. However, although those isolated myocytes were 
kept carefully in solutions that  avoided hypercontracture, the longitudinal intervals of t-tubules 
might be influenced by shortening of sarcomere length caused by small contraction of the myocytes 
during the fixing step. Along with the advancement of imaging techniques, further studies are 
necessary to clarify the mechanisms of t-tubules regulation in normal and diseased condition, and its 
effect on the microarchitecture of Ca handling.  
 
7.4.2 Colocalization of Na/K ATPase α2 isoform in t-tubule 
    The Na/K ATPase α2 isoform that preferentially localizes in the t-tubules is thought to control the 
local [Na] and regulate the nearby NCX, thus linking closely to the Ca handling
10,40,78,86
. The structural 
changes to t-tubules result in a functional alteration not only in systolic contraction but also in 
diastolic relaxation
40,42
.     
    Corresponding to the findings of Na/K ATPase α1 and α2 isoforms distribution in chapter 6, we 
find that changes to distribution of Na/K ATPase α2 isoforms correlate to those occurring to t-
tubules (Figure 7-5). Spatial frequency analysis of distribution of t-tubules and Na/K ATPase α1 and 
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α2 isoforms indicates that the α2 isoform and t-tubules have perfectly compatible regular intervals 
of staining (1.8 μm in the AC groups and 2.25 μm in the sham groups), whereas the distribution of 
Na/K ATPase α1 does not correspond to changes to t-tubules in heart failure. The present study 
shows evidence of a decline in Na/K ATPase function appearing early in the compensated 
hypertrophy stage and hypothesises that this might be a trigger mechanism for alterations in Ca 
handling. 
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Figure 7-5. Linear ROI measurement of immunofluorescence intensity of Na/K ATPase α1 and α2 
isoforms correlates to fluorescence intensity of WGA in the AC groups at 150 days after the 
operation.   
Na/K ATPase α1 immunofluorescence intensity measured by a fixed linear range of interest (ROI) 
shows not related to t-tubules distribution in the AC group (panel A). However, the Na/K ATPase α2 
immunofluorescence intensity shows closely related to the distribution of t-tubules in the AC group in 
heart failure. According to the spatial frequency analysis, the regular interval of distribution of Na/K 
ATPase α1 isoforms is 2.25 μm, whereas the intervals for Na/K ATPase α2 and t-tubules are both 1.8 
μm. 
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8 GENERAL DISCUSSION 
    Heart failure is an increasing health problem and affects a large population in the world. It 
accounts for a major cause of death and incurs a huge cost in treatment. Heart failure describes a 
series of symptoms including a progression of cardiac dysfunction eventually resulting in insufficient 
cardiac output to meet the circulation demand. At the level of the ventricular myocyte, the decline 
of contractile function is caused by a breakdown in Ca homeostatic mechanisms. The present study 
used an animal model of progressive heart failure in guinea pigs aiming to characterize the function 
of the whole heart in vivo, to determine the function of Ca regulatory proteins and cellular 
contraction mechanisms in vitro, and to investigate corresponding changes in Na/K ATPase function 
and isoform ratios at various time points during the progression from hypertrophy to heart failure. 
    Persistent increase in workload on the heart causes growth of ventricular myocytes resulting in 
increased ventricular wall thickness and mass. In chapter 3, in vivo observations found an increase in 
the heart weight / body weight ratio from the compensated hypertrophy stage.  Parallel 
echocardiographic examination showed normal fractional shortening at this stage. After 150 days, 
the properties of the hypertrophied myocardium become abnormal and its contractile function 
becomes impaired and eventually left ventricular failure ensues. Our data also show progressive 
alterations in the fractional shortening and the morphology of the heart. Left side systolic 
dysfunction occurs initially, followed by diastolic dysfunction causing right side heart failure with 
pulmonary congestion.    
    Prolongation of APD appears at the hypertrophied stage   when myocytes have increased Ca 
transients as well as SR Ca content. These functional enhancements may be compensatory 
mechanisms to provide a sufficient cardiac output. However, along with the progression of the 
disease, these compensatory mechanisms become less effective, and finally all decline when end 
stage heart failure is reached. We observed that the Na/K ATPase pump function declines early at 
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the stage of compensated hypertrophy and continues to be reduced until end stage heart failure. 
The alteration of Na/K ATPase function might be the triggering mechanism to initiate the 
compensation. A simulation of the effects of decreased Na/K ATPase current in ventricular myocytes 
was performed by using the mathematical model LabHEART created by Bers and Puglisi
138,281-285
 
(http://www.labheart.org/). This model is based on the cell physiology of rabbit ventricular 
myocytes but these share many similarities with ventricular cells in the guinea pig.  In the model, the 
Na/K ATPase current was decreased by half to match our experimental findings. We used the model 
to investigate if our observed changes in Ca handling could be simply reproduced by decreasing the 
pump current. The increases in [Ca]i, transient occur by making only this alteration to pump current.  
There is an enhanced outward INCX which will make Ca release more efficacious and the increased 
influx will load the SR assuming there is no change to SERCA function at this early state in the 
hypertrophic process.  There is an enhanced release of Ca from the SR evidenced by the larger 
transient decrease in junctional SR Ca content.  These model observations support the experimental 
changes to Ca handling we found in our experiments (Figure 8-1). 
    Studies have shown that the α2 isoform plays an more important role in regulating Ca handing and 
is believed to distribute preferentially in the t-tubules, whilst the α1 isoform regulates bulk [Na]i and 
localizes predominantly at surface sarcolemma. In this study, the contribution of α1 and α2 isoforms 
to total pump current is not changed during the progression of HF. Although the 
immunocytochemistry showed similar findings to the functional study in that in HF, the expression of 
isoforms both decreased as did the sizes of their respective currents, the α1 and α2 isoforms 
distributed with different spatial frequency within the cell. The α1 isoforms maintain a location 
periodicity that corresponds with that of the t-tubules, and while the α2 isoforms show a gain of 
organizational periodicity over normal cells with a shorter interval in HF. Furthermore, the spatial 
frequencies of Na/K ATPase α2 isoforms and t-tubules distribution are perfectly matched whether in 
sham or AC group.  
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   T-tubule remodelling was also investigated during the development of heart failure. Loss of t-
tubules occurred in myocytes isolated from HF GPs. Additionally, a regular but more compact 
organization was observed with the preserved t-tubules. Corresponding to the results of 
immunochemical staining of Na/K ATPase α1 and α2 isoforms, the distribution intervals of the α2 
isoforms and t-tubules are both 2.25 μm and 1.8 μm in the sham and AC groups respectively. This 
finding supports that the α2 isoforms colocalize with t-tubules and play a more important role in 
regulating Ca handling, which is believed to be in conjunction with NCX function. 
    According to the above findings, the deterioration of contractile function and progression of heart 
failure might start from the disorganization and loss of t-tubules accompanied by the alteration of 
colocalized Na/K ATPase α2 isoforms and this triggers a series of compensation events culminating in 
the compensatory hypertrophy stage. Advanced understandings of NKA α isoforms expression and 
possible dysfunction of its regulatory protein- PLM, may clarify the mechanism that causes decline of 
NKA function, which could be a potential therapeutic target for heart failure treatment. Further 
investigation of mechanisms causing t-tubules remodelling, and its mechano-sensory response to 
haemodynamic changes, and molecular changes in the microarchitecture, are also areas of future 
work. 
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Figure 8-1. Changes to the Ca transient ([Ca]i), junctional SR Ca content  
9[Ca]jSR) and Na/Ca exchange current (INCX) in a mathematical model of a 
rabbit ventricular myocyte (LabHEART) in which the Na/K ATPase 
current has been reduced by 50%.  The cell was stimulated at 1 Hz to 
reach steady-state. 
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